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decisions are regulated. These findings have implications for leukemogenesis and immunity.
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ABSTRACT 
 
FATTY ACID METABOLISM MEDIATED BY 12/15-LIPOXYGENASE IS A  
 
NOVEL REGULATOR OF HEMATOPOIETIC STEM CELL FUNCTION AND  
 
MYELOPOIESIS 
 
Michelle Kinder 
 
Advisor: Ellen Puré 
 
Fatty acid metabolism governs critical cellular processes in multiple cell types. 
The goal of my dissertation was to investigate the intersection between fatty acid 
metabolism and hematopoiesis. Although fatty acid metabolism has been 
extensively studied in mature hematopoietic subsets during inflammation, in 
developing hematopoietic cells the role of fatty acid metabolism, in particular by 
12/15-Lipoxygenase (12/15-LOX), was unknown. The observation that 12/15-
LOX-deficient (Alox15) mice developed a myeloid leukemia instigated my studies 
since leukemias are often a consequence of dysregulated hematopoiesis. This 
observation lead to the central hypothesis of this dissertation which is that 
polyunsaturated fatty acid metabolism mediated by 12/15-LOX participates in 
hematopoietic development.  Using genetic mouse models and in vitro and in 
vivo cell development assays, I found that 12/15-LOX indeed regulates multiple 
stages of hematopoiesis including the function of hematopoietic stem cells (HSC) 
and the differentiation of B cells, T cells, basophils, granulocytes and monocytes. 
Within hematopoietic development, I concentrated on the mechanisms that 
underlie the defects in HSC function and monocyte development since these 
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defects likely contribute to the myeloid leukemogenesis in Alox15 mice. 
Interestingly, I determined that 12/15-LOX promotes HSC self-renewal and 
quiescence, which is associated with the activation of canonical Wnt signaling. 
Moreover, my studies demonstrate that 12/15-LOX-mediated redox signaling of 
SHP-2 and the transcription factor ICSBP/IRF-8 promotes monocyte 
development while inhibiting granulocyte development. This pathway is also 
conserved in IL-12p40 expression in macrophages. Therefore, I establish 12/15-
LOX as a critical regulator of hematopoiesis and provide insight into novel 
mechanisms whereby HSC function and monocyte cell fate decisions are 
regulated. These findings have implications for leukemogenesis and immunity.
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INTRODUCTION 
 Hematopoiesis is the dynamic process whereby all blood cells develop 
from a common progenitor, the hematopoietic stem cell (HSC). Under 
homeostatic conditions, hematopoiesis must continuously replenish billions of 
cells of the blood system daily including erythrocytes and neutrophils, which 
exhibit short half-lives. As HSC are relatively rare, but there is an abundance of 
blood cells, the process of hematopoiesis must be tightly regulated to produce 
appropriate numbers of each blood cell type. Moreover, the process of 
hematopoiesis must adapt to stresses such as infection. Dysregulation of 
hematopoiesis can result in immunodeficiencies, anemias or leukemias. 
Therefore, it is important to study the molecular processes that underlie normal 
and malignant hematopoietic development. In this dissertation, I define 
polyunsaturated fatty acid metabolism mediated by 12/15-Lipoxygenase (12/15-
LOX) as a critical regulator of hematopoiesis. Specifically, I elucidate the 
mechanisms whereby 12/15-LOX regulates HSC function and myelopoiesis. 
Hematopoietic Stem Cells 
HSCs are multipotent cells that give rise to all of the cells of the blood 
during hematopoiesis (Figure 1). HSCs possess the unique ability to undergo 
asymmetric division by proliferating in a fashion that preserves self-renewal and 
also allows for differentiation to give rise to mature blood cells. Because markers 
for HSCs have been identified (Wilson et al., 2007) and assays for measuring 
HSC function are well defined (Purton and Scadden, 2007), 
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HSCs are an attractive model system for understanding tissue stem cells in 
general. The study of HSCs provides insight into the regulation of stem cells 
during infection, aging, and oncogenesis. 
HSCs have been identified using various phenotypic markers. Although 
murine HSCs are enriched within the Lin-Sca1+cKit+ (LSK) cell compartment, 
they can be further subdivided both functionally and phenotypically into multiple 
subtypes by a combination of other markers including CD34 (Morel et al., 1996), 
Flt3 (Yang et al., 2005) and the signaling lymphocyte activation molecule (SLAM) 
markers CD48 and CD150 (Kiel et al., 2005). Long-term HSCs (LT-HSC) are the 
most primitive HSC and fully reconstitute the hematopoietic compartment of 
lethally irradiated animals. LT-HSCs are highly enriched (1 of every 2 cells) within 
the subset of cells that are identified based on phenotypic profile LSKFlt3-CD48-
CD150+CD34- (Wilson et al., 2007). They reside in a hypoxic niche and are 
generally quiescent (Cheshier et al., 1999; Wilson et al., 2007) Recent studies 
have subdivided the LT-HSC compartment into dormant and activated LT-HSC 
based on cell retention assays using bromodeoxyuridine (BrdU) and histone-2B-
GFP labeling. Dormant LT-HSCs rarely divide but can become activated to 
undergo asymmetric division in order to respond to environmental stresses such 
as chemotherapy treatment (for example, 5-fluorouracil, 5-FU), cytokine 
stimulation and hematopoietic reconstitution. When stimulation wanes and 
homeostasis is reestablished, activated LT-HSCs become dormant again (Wilson 
et al., 2008). In comparison, short-term HSCs (ST-HSC) have decreased ability 
for long term reconstitution of lethally irradiated animals and are more 
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proliferative than LT-HSCs (Figure 1). ST-HSCs can further differentiate to 
become multipotent progenitors (MPP), which retain the ability to generate all 
blood lineages, but lose the potential to self-renew. Subpopulations of MPP may 
differ in their ability to differentiate into various blood cell types (Wilson et al., 
2007).  
One way of measuring HSC function is by measuring their ability to 
reconstitute lethally irradiated hosts. There are multiple factors that contribute to 
HSC function in this regard (Figure 2). The numbers, homing and survival of 
HSCs can effect their ability to function. Defective asymmetric division also 
effects HSC function. Inability to self-renew or differentiate compromises HSC 
function. The ability of HSCs to self-renew and differentiate is regulated through 
their environmental niche, cytokine signaling and the orchestrated activities of 
various transcription factors including growth factor independent-1 (Gfi-1), Bmi, 
homeobox B4 (Hox4b) and Pu.1 (Blank et al., 2008). However, less is known 
about the signaling pathways that regulate HSC function. In this dissertation, I 
demonstrate that signaling downstream of 12/15-LOX-mediated fatty acid 
metabolism regulates HSC self-renewal. 
The unique capacity of HSCs to both differentiate and self-renew is closely 
related to their proliferative capacity (Ficara et al., 2008; Nemeth et al., 2006). 
Highly proliferative HSCs are less efficient at reconstituting lethally irradiated 
mice (Passegue et al., 2005). Thus, HSCs that lack cell cycle inhibitors required 
to maintain quiescence, such as p21cip/WAF, are functionally defective  
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(Cheng et al., 2000). This dissertation will demonstrate that HSCs from 12/15-
LOX-deficient mice, Alox15, exhibit defective quiescence and HSC function. 
Canonical Wnt Signaling 
 As mentioned, little was known about signaling pathways that regulate 
HSC function. Canonical Wnt signaling is one such pathway that has been 
implicated to regulate HSC function although its importance remains debated. 
Canonical Wnt signaling is believed to regulate HSC self-renewal and is known 
to play a role in other cell types, such as promoting B and T lymphocyte 
development (Staal and Sen, 2008) and enhancing self-renewal of tumor cells 
(Fodde and Brabletz, 2007). There are 19 defined Wnt ligands that are lipid 
modified by palmitoylation, which is required for its secretion from the cell 
(Takada et al., 2006; Willert et al., 2003). Wnt ligands act on 10 different Frizzled 
receptors and two low-density lipoprotein receptor-related protein (LRP) co-
receptors.  
 Wnt signaling is based on the availability of the ligands, receptors and 
secondary messengers. Up to 10 signaling pathways have been implicated 
downstream of Wnt signaling. The canonical signaling pathway results in 
stabilization and nuclear translocation of the transcription factor β–catenin 
(Malhotra and Kincade, 2009). During canonical signaling, ligands such as 
Wnt3a or Wnt 10b activate the frizzled receptor and LRP co-receptor to activate 
disheveled. Disheveled functions by inhibiting the β–catenin destruction complex 
which is composed of axin, glycogen synthase kinase 3 (GSK-3β) and 
adenomatous polyposis coli (APC). In the absence of canonical Wnt 
7 
 
signaling, this complex binds and phosphorylates β–catenin targeting it for 
ubiquitination and subsequent proteolysis. When members of this complex such 
as axin are over-expressed, β–catenin protein is degraded and signaling is 
reduced, resulting in decreased HSC function and self-renewal (Reya et al., 
2003). However, in the presence of canonical Wnt signaling β–catenin and a 
related protein, γ–catenin, are stabilized and can translocate to the nucleus 
where it acts as a co-activator for the lymphoid enhancer factor (LEF) and T cell 
factor (TCF) transcription factors (Malhotra and Kincade, 2009). The non-
canonical Wnt signaling pathway is activated in part by the Wnt5a ligand and can 
inhibit canonical Wnt signaling (Nemeth et al., 2007). 
 The role of canonical Wnt signaling in HSC function has been 
controversial because inducible deletion of β–catenin and inducible co-deletion of 
β–catenin/γ–catenin using Mx-Cre had little effect on HSC function (Cobas et al., 
2004; Jeannet et al., 2008; Koch et al., 2008). However, in these studies, the 
LEF/TCF reporter was still active (Jeannet et al., 2008). On the other hand, 
recent evidence points to a critical role for canonical Wnt signaling in regulation 
of HSC quiescence and self-renewal. For instance, deletion of β–catenin using 
Vav-cre, resulted in defective self-renewal of LT-HSCs (Zhao et al., 2007). HSC 
function was also compromised due to defective self-renewal when the canonical 
ligand Wnt3a was deleted (Luis et al., 2009). Over-expression of Dickkopf-1, an 
inhibitor of canonical Wnt signaling, increased HSC proliferation and decreased 
HSC self-renewal (Fleming et al., 2008). Conversely, when Wnt signaling was 
elevated, such as in Hmgb3-deficient HSCs, the ability of HSCs to self-renew 
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and repopulate following hematopoietic stress were enhanced (Nemeth et al., 
2006). Taken together, these data support a role of canonical Wnt signaling in 
HSC self-renewal. This dissertation defines 12/15-LOX as a novel regulator of 
canonical Wnt signaling.  
Myelopoiesis 
 Myelopoiesis is the process whereby myeloid cells, monocytes and 
granulocytes, are generated. Although originally thought of as a linear pathway, 
recent studies have shown that immature intermediates once thought to give rise 
exclusively to cells of the lymphoid lineage also possess myeloid cell potential 
(Bell and Bhandoola, 2008). These studies have caused the field to rethink the 
hierarchical model of myeloid cell differentiation (Ceredig et al., 2009). However, 
in order to concentrate on myeloid lineage differentiation rather than cells arising 
during lymphoid differentiation, I will refer to the classical model of myeloid cell 
differentiation (Figure 3). However, it is important to note that the lineage 
decisions between monocytes and granulocytes remain a mutually exclusive cell 
fate decision that is conserved throughout various models of hematopoiesis.  
 HSCs are multipotent and can differentiate into any hematopoietic lineage. 
However, as HSC differentiate they lose their ability to self-renew and are more 
restricted in their differentiation potential. HSC differentiate into MPP, which lack 
the ability to self-renew but can still differentiate into all lineages. MPP initiate T 
cell differentiation by seeding the thymus (Schwarz and Bhandoola, 2004), 
initiate B cell differentiation by differentiating into common lymphoid progenitors 
(CLP) (Kondo et al., 1997) or initiate myeloid cell differentiation by becoming 
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common myeloid progenitors (CMP) (Akashi et al., 2000). CMPs can support 
erythroid cell differentiation by becoming megakaryocyte-erythroid progenitors 
(MEP) and subsequently produce megakaryocytes, red blood cells and platelets. 
On the other hand, CMPs can differentiate to produce granulocyte-macrophage 
progenitors (GMP), which in turn produce either granulocytes or macrophages 
and types of dendritic cells (Akashi et al., 2000).  
 The process of myelopoiesis is regulated by cytokines and by transcription 
factors (Figure 3). The cytokine granulocyte-macrophage stimulating factor (GM-
CSF) promotes the production of GMP, while granulocyte colony stimulating 
factor (G-CSF) and macrophage colony stimulating factor (M-CSF) instruct 
granulocyte and monocyte lineage fate decisions, respectively. The signaling 
pathways of G-CSF and M-CSF have recently been elucidated. M-CSF activates 
phospholipase Cγ2 (PLCγ2), which in turn stimulates extracellular signal-
regulated kinase (Erk) activation. Activated Erk leads to transcriptional activity of 
c/EBPα:c-fos and c-jun heterodimers and Egr-1 which drives monocyte 
differentiation. On the other hand, G-CSF stimulates signal transducers and 
activators of transcription 3 (Stat3) activation leading to phosphorylation and 
increased activity of the phosphatase Src homology 2-containing tyrosine 
phosphatase-2 (SHP-2) and formation of CCAAT/enhancer binding protein-α 
(c/EBPα) homodimers, which mediate transcription of genes that promote 
monocyte differentiation (Jack et al., 2009). Though the exact role of SHP-2 
during granulopoiesis is not known, it is known to dephosphorylate and 
subsequently inhibit the transcriptional activity of interferon regulatory factor-
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8 (IRF-8, also known as interferon consensus sequence binding protein, ICSBP), 
which is a critical regulator of monocyte differentiation (Huang et al., 2006; 
Tamura and Ozato, 2002). Interestingly, SHP-1 and SHP-2 are subject to 
oxidative modification that results in inactivation (Chen et al., 2009a; Heneberg 
and Draber, 2005; Kwon et al., 2005; Weibrecht et al., 2007). Moreover, reactive 
oxygen species (ROS) generated by lipoxygenases have been implicated in 
oxidative inactivation of SHP-2 during density dependent inhibition of cell growth 
(Pani et al., 2000). In chapter 3, I demonstrate that inhibition of SHP-1/2 restores 
monocyte development and interleukin-12p40 (IL-12p40) production in Alox15 
cells, suggesting a pathway by which 12/15-LOX-mediated redox signaling 
regulates myelopoeisis and inflammation through ICSBP/IRF-8 
 As described above, cytokines stimulate signaling pathways that result in 
the activation of transcription factors. The cell fate decision between monocyte 
and granulocytes are mutually exclusive and pathways that promote one cell fate 
often inhibit the other. For instance, the transcription factors early growth 
response factor-1 (Egr-1), Egr-2, ICSBP/IRF-8, NGFI-A binding protein 2 (Nab-
2), c-Jun and HoxA10 promote monocyte differentiation and repress granulocyte 
differentiation while Gfi-1 promotes granulocyte differentiation and inhibits 
monocyte differentiation (Friedman, 2007; Hock et al., 2003). In addition, the 
relative levels of transcription factors function as a rheostat to control 
differentiation; increased levels of PU.1 promote monocyte differentiation while 
higher levels of the transcription factor C/EBPα promote granulocyte 
differentiation (Dahl et al., 2003).  
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ICSBP/IRF-8 
The interferon regulatory factor family of transcription factors is known to 
regulate cell fate decisions and immune regulation (Tamura et al., 2008). One 
such family member, ICSBP/IRF-8 is an immune cell specific transcription factor 
important in development of multiple hematopoietic cell types. ICSBP/IRF-8-
regulates B cell, dendritic cell and monocyte development and absence of 
ICSBP/IRF-8 in ICSBP/IRF-8-deficient mice leads to deficiencies of these 
populations (Lu et al., 2003; Tsujimura et al., 2002). Moreover, the disruption of 
myeloid cell development in ICSBP/IRF-8-deficient mice results in chronic 
myelogenous leukemia (CML)-like myeloproliferative disorder that progresses to 
a blast crisis (Holtschke et al., 1996).  
The expression of ICSBP/IRF-8 and other members of the interferon 
regulatory factor family members are activated by interferon-γ (IFN-γ) signaling 
through Stat1 (Kanno et al., 1993). ICSBP/IRF-8 consists of 3 domains: DNA 
binding domain, transcription repressor domain and an IRF-association domain 
(Sharf et al., 1995). IRF-8 both represses and activates transcription of distinct 
subsets of genes. ICSBP/IRF-8 activates transcription of genes including 
neurofibromin (NF-1) (Zhu et al., 2004), p15INK4b (Schmidt et al., 2004), 
phagocyte oxidase91 (phox91) (Eklund et al., 1998), phox67 (Eklund and Kakar, 
1999), B-lymphocyte-induced maturation protein-1 (Blimp-1) (Tamura et al., 
2003) and IL-12p40 (Wang et al., 2000) and represses transcription of other 
genes including bcl-xl (Gabriele et al., 1999), bcl-2 (Burchert et al., 2004), and 
disabled-2 (Dab2) (Rosenbauer et al., 2002).  
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ICSBP/IRF-8-transcriptional activity is regulated post-translationally on 
multiple levels. The gene targeting and transcriptional activity of ICSBP/IRF-8 is 
conferred in part by its binding to other transcription factors such as PU.1 and 
other IRF family members (Eklund et al., 1998). The association of ICSBP/IRF-8 
with other transcription factors is also believed to regulate whether it functions as 
a transcriptional activator or repressor. Tyrosine phosphorylation of ICSBP/IRF-8 
inhibited its direct binding to DNA but allowed for ICSBP/IRF-8 to bind DNA in 
association with IRF-1 or IRF-2 (Sharf et al., 1997). On the other hand, the 
phosphatases SHP-1 and SHP-2 de-phosphorylated ICSBP/IRF-8 causing 
functional inactivation by inhibiting its association with other transcription factors 
such as PU.1 (Kautz et al., 2001; Huang et al., 2006). One mechanism whereby 
oncogenic constitutively active SHP-2 contributes to myeloid leukemia is by 
decreasing levels of the ICSBP/IRF-8-mediated gene target NF-1, which in turn 
increases cytokine sensitivity (Huang et al., 2006; Koenigsmann et al., 2009). 
Moreover, ICSBP/IRF-8 is subject to regulation by proteosomal degradation 
through Cbl ubiquitin ligase after LPS/IFNγ stimulation (Xiong et al., 2005). 
Lastly, previous data from our laboratory demonstrated that ICSBP/IRF-8 is also 
regulated at the level of nuclear accumulation. 12/15-LOX-deficient myeloid 
splenocytes exhibited similar levels of total but decreased nuclear accumulation 
of ICSBP/IRF-8. This regulation was mediated in part by PI3-K (Middleton et al., 
2006b). In this dissertation, I elucidate that 12/15-LOX regulates ICSBP/IRF-8 
nuclear accumulation through a redox-dependent mechanism.  
ICSBP/IRF-8 and its target genes are implicated in HSC function. 
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ICSBP/IRF-8 expression is decreased in aging HSC (Stirewalt et al., 2008), 
which are known to be functionally compromised (Roobrouck et al., 2008). In 
addition, ICSBP/IRF-8 represses Dab2 transcription, and ICSBP/IRF-8-deficient 
cells express high levels of Dab2 (Rosenbauer et al., 2002). Others have shown 
that Dab2 negatively regulates canonical Wnt signaling by stabilizing axin and 
the β-catenin degradation complex while inhibiting disheveled (Hocevar et al., 
2003; Jiang et al., 2008). Our data demonstrate that Dab2 expression is also 
increased in Alox15 HSC, which results in decreased canonical Wnt signaling. As 
described above, canonical Wnt signaling regulates HSC function and may 
contribute to the defects in Alox15 HSC.  
ICSBP/IRF-8 critically promotes monocyte differentiation in conjugation 
with PU.1 by activating genes that stimulate monocyte differentiation while 
inhibiting genes that promote granulocyte differentiation (Tamura et al., 2000). 
ICSBP/IRF-8-deficient mice exhibited defective monocyte differentation and 
enhanced granulocyte differentiation that was corrected by retrovirally restoring 
IRF-8 expression (Tsujimura et al., 2002).  Moreover, ICSBP/IRF-8-deficient 
mice developed a granulocytic chronic myelogenous leukemia (CML)-like 
leukemia that progresses into a blast crisis (Holtschke et al., 1996). In addition to 
its tumor suppressor role in murine leukemia, ICSBP/IRF-8 may also function as 
a tumor suppressor in human CML. ICSBP/IRF-8 is down-regulated in human 
CML (Schmidt et al., 1998; Schmidt et al., 2001) and has been shown to 
antagonize BCR-ABL-induced oncogenesis (Hao and Ren, 2000; Tamura et al., 
2003; Burchert et al., 2004). Interestingly, ICSBP/IRF-8 also functions as a 
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tumor suppressor in other leukemias (Gurevich et al., 2006; Ma et al., 2006; 
Konieczna et al., 2008; Schwieger et al., 2002).  
ICSBP/IRF-8 critically mediates immunity by transcribing IL-12p40 mRNA 
in antigen presenting cells, dendritic cells and macrophages (Hein et al., 2000) 
(Jayakumar et al., 2008; Scharton-Kersten et al., 1997). Loss of IL-12p40 gene 
expression in IRF-8/ICSBP-deficient mice results in susceptibility to myriad of 
viruses, parasites and bacteria including vaccinia virus, lymphocytic 
choriomeningitis virus (Holtschke et al., 1996) Listeria monocytogenes (Fehr et 
al., 1997), Yersinia enterocolitica (Hein et al., 2000), Toxoplasma Gondii 
(Scharton-Kersten et al., 1997), and Leishmania major (Giese et al., 1997). 
Because of the development of a myeloproliferative disease in ICSBP/IRF-8 
deficient mice, less is known about the role of ICSBP/IRF-8 during chronic 
inflammatory events. Development of a floxed ICSBP/IRF-8 mouse would 
facilitate further studies into the role of ICSBP/IRF-8 in immunity and chronic 
inflammation. 
Myeloproliferative Neoplasms  
 Myeloproliferative neoplasms (MPN) are a result of defective myelopoiesis 
and are characterized by a clonal expansion of myeloid subsets. Human MPNs 
include CML, chronic neutrophilic leukemia, polycythemia vera, primary 
myelofibrosis, essential thrombocythemia, chronic eosinophilic leukemia, 
mastocytosis, and unclassifiable MPNs (Thiele, 2009).  
 Defects in transcription factors that regulate myelopoiesis contribute to 
myeloid leukemias in both mice and humans. For instance, ICSBP/IRF-8 
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regulates monocyte differentation and inhibits granulocyte differentiation (Tamura 
et al., 2000; Tsujimura et al., 2002). In ICSBP/IRF-8-deficient mice, a 
granulocytic CML-like myeloproliferative neoplasm results (Holtschke et al., 
1996). Moreover, during human CML, ICSBP/IRF-8 expression is decreased 
(Schmidt et al., 1998). Similarly, the transcription factor JunB regulates 
myelopoiesis and loss of JunB in the myeloid lineage leads to a CML-like MPN 
(Passegue et al., 2001). Human CML is also associated with decreased JunB 
expression (Hoshino et al., 2009; Yang et al., 2003). Another example is PU.1, 
which regulates early myeloid differentiation. PU.1-deficient mice have an early 
block in myeloid differentiation and disruption of PU.1 results in an acute myeloid 
leukemia in both mice and humans (Anderson et al., 1998; Mueller et al., 2002).  
 Alterations in cell signaling can also underlie myeloid leukemogenesis. 
Loss of NF-1 gene expression in both mice and humans results in hyperactive 
Ras and cytokine signaling leading to juvenile chronic myelogenous leukemia 
(Shannon et al., 1994; Kalra et al., 1994; Bollag et al., 1996). Similarly, activating 
mutations in SHP-2 also stimulates Ras activation resulting in cytokine 
hypersensitivity and myelogenous leukemia (Niihori et al., 2005; Loh et al., 2004; 
Schubbert et al., 2005). Polycythemia vera, primary myelofibrosis and essential 
thrombocythemia represent related MPNs often caused by activating mutations 
in Jak2 (Levine and Gilliland, 2008). On the other hand, human CML is 
characterized by presence of a translocation known as the Philadelphia 
chromosome involving chromosomes 9 and 22. The Philadelphia chromosome is 
a fusion of Bcr to Abl that results in a constitutively active tyrosine kinase. 
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Bcr-Abl activates multiple signaling pathways to promote oncogenic signaling 
including activation of PI3-K and Ras signaling (Ren, 2005). Treatment of CML 
with the tyrosine kinase inhibitor imatinib has resulted in about 80% clinical and 
cytogenic remissions; however, treatment is not curative (Vardiman, 2009).  
 Since HSCs are the only stage at which self-renewal can occur during 
normal hematopoiesis often the mutations that lead to leukemia are found in 
HSCs. For instance, JunB deficiency must be in the HSCs and not in later stages 
of hematopoiesis for leukemia to result (Passegue et al., 2004). Moreover, 
deficiency of the tumor suppressor phosphatase tensin homolog (PTEN) in HSCs 
results in a myeloid leukemia (Yilmaz et al., 2006). In human leukemia, the Bcr-
Abl translocation is found in HSCs and drives the chronic phase of disease. 
However, a secondary mutation develops in GMPs that confers the ability to self-
renew and drives the blast crisis disease phase  (Jamieson et al., 2004). 
Fatty acid metabolism 
 Metabolism describes the chemical processes in living organisms that 
support cellular and organismal functions. Fatty acid metabolism describes 
chemical reactions that involve fatty acids, such as those found in triglycerides 
and membrane phospholipids. Triglycerides serve to generate energy for the 
body and are stored in adipose tissue. Meanwhile, the fatty acid components of 
cell membranes can be directly modified enzymatically or catabolized through the 
actions of phospholipases to generate free fatty acids. Fatty acid metabolism 
generates secondary messengers that serve as signaling molecules to regulate 
cellular processes including vascular homeostasis, platelet aggregation and 
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inflammatory responses.  
 During polyunsaturated fatty acid metabolism, lipid substrates such as 
arachidonic acid (AA) or lineolic acid are released from the cell membranes by 
phospholipase A2. The major product AA is then metabolized through the action 
of oxidative enzymes including cytochrome p450, cyclooxygenases, and 
lipoxygenases to produce multiple bioactive lipid mediators including 
eicosanoids, prostaglandins, leukotrienes and lipoxins (Figure 4). These products 
are generated in a cell-context dependent manner and can signal in both 
autocrine and paracrine fashions (Harizi et al., 2008). Reactive oxygen species 
(ROS) are generated as a byproduct of the oxidation step of AA and as the lipid 
products are further metabolized by gluthathione reductase activity (Kim et al., 
2008) (Figure 4). The myriad lipid mediators often have opposing functions and 
hence signaling is dependent on the relative concentration of multiple lipid 
mediators (Harizi et al., 2008).  
Cytochrome p450 and Cyclooxygenases 
 The cytochrome p450 superfamily is composed of 57 members and is 
expressed in multiple cell types including liver, adrenal glands, and peripheral 
blood leukocytes where its expression can be induced by various stimuli (Dy and 
Schneider, 2004). Cytochrome p450 metabolizes AA to produce 
hydroxyeicosatetraenoic acids (HETE) and epoxyeicosatrienoic acids (EET). 
Cytochrome p450 functions in angiogenesis and plays a protective role during 
myocardial and cerebral ischemia. Moreover, lipid mediators produced by 
cytochrome p450 have been shown to play an anti-inflammatory role in 
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endothelium and in the kidney (Spector, 2009). Cytochrome p450 lipid products 
exert their effects extracellularly, through a putative EET receptor or by binding 
other lipid receptor agonists which are coupled to signaling pathways, and 
intracellularly by acting directly on ion channels, cell signaling proteins, 
transcription factors or by incorporation into membrane phospholipids. 
Interestingly, cytochrome p450 lipid products can have opposing functions. For 
example, 20-HETE acts on smooth muscle cells as a vasoconstrictor while EET 
acts as a vasodilator (Kroetz and Zeldin, 2002).  
 Cyclooxygenases catabolize AA to produce prostaglandins, which exert 
their pleiotropic effects by binding to multiple G-protein coupled receptors that 
vary in their secondary signaling pathways and cellular expression (Harizi et al., 
2008). Cyclooxygenase-1 (COX-1) is constitutively expressed in most cell types 
and is highly expressed in endothelium, monocytes, platelets, renal collecting 
tubules and seminal vesicles. The expression of cyclooxygenase-2 (COX-2) is 
inducible and restricted to cells involved in reproduction, immunity, renal 
physiology, neutrotransmission, bone resorption and pancreatic secretion.  COX-
2 is induced by multiple proliferative and inflammatory stimuli including tumor 
necrosis factor-α, lipopolysaccharide (LPS) and IL-1 and decreased by 
glucocortioids and anti-inflammatory stimuli (Smith et al., 2000). Nonsteroidal 
anti-inflammatory drugs, such as aspirin and ibuprofen, target the COX isoforms 
as a treatment for pain, fever, and inflammation (Rouzer and Marnett, 2009). 
COX-2 is pro-inflammatory in peripheral tissues and participates in inflammatory 
diseases such as cancer and in rheumatoid arthritis (Obukowicz and 
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Ornberg, 1999; Rouzer and Marnett, 2009; Tuynman et al., 2008). COX-2 
specific inhibitors have been developed to treat chronic inflammation but its use 
is limited due to cardiovascular toxicity, which is associated with decreased PGI2 
production in the blood vessel wall (Rho et al., 2009; Rouzer and Marnett, 2009). 
On the other hand, COX-2 can also decrease inflammation in a cell-context 
dependent manner. For instance, COX-2 through prostaglandin E2 (PGE2) can 
decrease inflammation in secondary lymphoid organs by decreasing IL-12p40 
production through an IL-10 dependent mechanism in dendritic cells (DC), 
inducing forkhead box P3+ (FoxP3) regulatory T cells, suppressing natural killer 
(NK) cell IFNγ production and inducing B cell immunoglobulin (Ig)-class switching 
(Harizi et al., 2008; Harizi and Gualde, 2006). 
Lipoxygenases 
 Lipoxygenases are a diverse class of oxidative enzymes that catalyze 
oxygenation of AA and lineolic acid to generate numerous hydroperoxy-
eicosatetraeoic acid (HpETE) intermediates (Conrad, 1999). 5-Lipoxygenase (5-
LOX) is an enzyme primarily expressed in leukocytes that catalyzes the 
conversion of AA to 5-HpETE and subsequently catalyzes the reaction of 5-
HpETE to generate leukotriene A4. 5-LOX is bound by 5-lipoxygenase activating 
protein that enhances its substrate binding. Leukotriene A4 is subsequently 
converted to leukotriene C4 (LTC4) in cells that express LTC4 synthase such as 
mast cells, eosinophils, and endothelial cells or converted to leukotriene B4 in 
cells that express LTA4 hydrolase such as neutrophils and monocytes. LTC4 can 
be further metabolized to produce LTD4, and LTE4. Leukotrienes are 
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released from the cell by protein transporters and signal by binding G-coupled 
protein receptors BLT1, BLT2, cysLT1, cysLT2 (Peters-Golden and Henderson, 
2007).  The leukotrienes produced depend on cellular context, and their signaling 
depends on the expression of receptors on neighboring cells. Leukotrienes 
stimulate leukocyte recruitment of multiple cell types to inflammatory sites and 
their subsequent activation (Islam et al., 2006; Tager et al., 2000; Lee et al., 
1999; Shin et al., 2006; Taube et al., 2006). Leukotrienes also increase Th2 
inflammatory responses, vascular permeability, and bronchoconstriction and 
contribute to the pathogenesis of asthma, cardiovascular disease, arthritis and 
cancer (Hyde and Missailidis, 2009; Peters-Golden and Henderson, 2007; 
Woszczek et al., 2005; Williams and Spector, 2009). Moreover, inhibitors of 5-
LOX and cysLT1 are used in the treatment of asthma (Israel et al., 1996; Schmidt 
et al., 2005; Van Schoor et al., 1997).  
5-LOX in concert with 15-lipoxygenase (15-LOX) or 12-lipoxygenase, 
generates lipoxin A4 and lipoxin B4. Not only does lipoxin production decrease 
leukotreine production, generally, the actions of lipoxins function to oppose the 
actions of leukotrienes (Serhan, 2005). Lipoxins control the resolution of 
inflammation by stimulating anti-inflammatory pathways such as inhibiting 
neutrophil infiltration, acting as a chemoattractant for macrophages and 
stimulating their uptake of apoptotic cells, and decreasing production of pro-
inflammatory cytokines such as IL-1 and IL-8 (Papayianni et al., 1996; Godson et 
al., 2000; Lee et al., 1989; Bonnans et al., 2002; Machado et al., 2008; Maddox 
et al., 1997; Sodin-Semrl et al., 2000; Wu et al., 2005). These actions play a 
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role in the resolution of inflammatory events such as airway inflammation, 
asthma, arthritis, and gastrointestinal disease (Kronke et al., 2009; Serhan, 2005; 
Janakiram and Rao, 2009; Levy et al., 2002; Wallace et al., 2005). 
12/15-Lipoxygenase 
In the process of metabolizing polyunsaturated fatty acids, 12/15-
lipoxygenase (12/15-LOX) generates multiple products. 12/15-LOX introduces 
molecular oxygen into AA and linoleic acids to produce bioactive labile lipid 
intermediates such as 12(S)-hydroperoxyeicosatetraenoic acid (12(S)-HpETE), 
15(S)-hydroperoxyeicosatetraenoic acid  (15(S)-HpETE) and 13(S)-
hydroperoxyoctadecadienoic acid  (13(S)-HpODE). These intermediates are 
rapidly reduced by glutathione reductase to release ROS and produce additional 
bioactive lipid metabolites, including 12(S)-HETE, 15(S)-HETE, 13(S)-HODE, 
lipoxins, and hepoxilins (Kuhn and O'Donnell, 2006) (Figure 5). 12/15-LOX can 
also oxidize membrane-bound fatty acids directly to produce additional fatty acid 
products. Moreover, novel products of 12/15-LOX are still being defined (Wei et 
al., 2009).  
Humans have multiple 12/15-lipoxygeneases, including leukocyte-type 12-
lipoxygenase, 15-lipoxygenase-1 and 15-lipoxygenase-2 all of which have the 
ability to produce 12(S)-HETE as well as 15(S)-HETE albeit in different ratios. 
15-Lipoxygenase-1 is expressed in reticulocytes, leukocytes, bronchial epithelial 
cells and carcinoma cells while 15-lipoxygenase-2 is not expressed in peripheral 
leukocytes but rather in liver, spleen, kidney, intestines, testis, ovary, muscle, 
heart and brain. 15-Lipoxygenase-1 and 15-lipoxygenase-2 are co-
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expressed in bronchial epithelial cells (Chanez et al., 2002). Leukocyte-type 12-
lipoxygenase is expressed in leukocytes, liver, lung, and endothelial cells (Funk 
et al., 1992). On the other hand, mice possess a single leukocyte-type 12/15-
lipoxgenase, which produces 12(S)-HETE and 15(S)-HETE at a ratio of 3:1 
(Chen et al., 1994). Therefore, murine 12/15-LOX and human 12- and 15-
lipoxygenases differ in lipid mediator production. Some of the effects of murine 
12/15-LOX are analogous to human leukocyte 12-lipoxgenase (Mullin et al., 
2007) while others map to 15-lipoxygenase-1 (Kelavkar et al., 2004). Therefore, 
in order to elucidate the relevant human counterpart, it is important to understand 
the products of murine 12/15-LOX that mediate its biological effects. Platelet-type 
12-lipoxygenease and epidermal-type 12-lipoxygenase are additional 
lipoxygenases found in humans and mice but are less related to leukocyte-type 
12-lipoxygenase and 15-lipoxygenase-1 both by sequence and function.  
12/15-Lipoxygenase products can activate multiple signaling pathways 
resulting in activation of transcription factors including peroxisome proliferator-
activated receptor γ, IRF-8, and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) that then modulate gene transcription (Huang et al., 
1999; Middleton et al., 2006a) (Figure 6). 12(S)-HETE and 15(S)-HETE both 
activate protein kinase C (PKC) while 15(S)-HETE and 13(S)-HODE activate the 
mitogen activated protein kinase (MAPK) pathway. Products of 12/15-LOX can 
also be incorporated into cellular membranes to regulate cellular functions 
(Takata et al., 1994; Kuhn and Brash, 1990; van Leyen et al., 1998). 12/15-LOX 
lipid mediator signaling events have pleiotropic affects on myriad cell types. 
26 
 
27 
 
Notably, 12/15-LOX regulates the pathogenesis of atherosclerosis, psoriasis, 
arthritis, glomerular nephritits, and airway inflammation (Conrad, 1999).  
Reactive Oxygen Species 
ROS are another important product of fatty acid metabolism. Cellular 
ROS, such as superoxide O2-, hydrogen peroxides H2O2, hydroxyl radial OH- and 
hypochlorous acid HOCl, are produced through the actions of nicotinamide 
adenine dinucleotide phosphate oxidases (NAPDH oxidases), mitochondria and 
fatty acid metabolism (Ghaffari, 2008; Haddad, 2002a). ROS regulate multiple 
signaling processes. For instance, ROS play a paramount role during phagocyte 
killing of bacteria in a process known as the oxidative burst. ROS can also be 
highly toxic to cells by causing oxidative stress resulting in cellular and tissue 
damage through oxidative modification of cellular components and activation of 
apoptosis. Therefore, the levels of cellular ROS are tightly controlled by the 
presence of anti-oxidants. Cellular anti-oxidants are present in various forms 
including reducing agents such as vitamin E, vitamin C, glutathione and including 
enzymes such as catalase, superoxide dismutase and peroxidases. For 
example, superoxide is catalyzed by superoxide dismutase to produce hydrogen 
peroxide H2O2, which is further metabolized by catalase to produce molecular 
oxygen and water (Ghaffari, 2008). Inhibition of anti-oxidants in the cell can result 
in oxidative stress (Jones, 2008). 
ROS mediate redox reactions, which is the shuffling of electrons in 
chemical reactions. Redox signaling is always occurring within the cell in 
homeostatic conditions to regulate essential cellular functions. For instance, 
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redox signaling in the electron transport chain in mitochondria generates the 
majority of energy in the body as adenosine triphosphate (Hancock, 2009). 
Redox signaling also regulates protein function. Cysteines within proteins contain 
a thiol residue that is susceptible to oxidative modification, which can result in the 
formation of disulfide bonds if two cysteine residues are in close proximity. 
Oxidative modification of a protein residue can have multiple effects on protein 
function. If the residue is in a catalytic site of an enzyme, oxidative modification 
can cause functional inactivation. If the residue is in an allosteric site, oxidative 
modification can alter protein conformation and function as a rheostat for protein 
activity. Moreover, oxidative modification of proteins can alter protein binding and 
result in decreased or increased binding to substrates such as DNA, membranes, 
cytoskeleton or other proteins (Jones, 2008).  
In theory, redox signaling can regulate any protein with an accessible 
cysteine residue. There is an average of 1.9 cysteine residues per protein in 
humans. Therefore, redox signaling could theoretically regulate many proteins. 
Because of the need for cysteine residues to be accessible it is likely that only 
10-20% of human proteins are in fact directly regulated by redox signaling 
(Jones, 2008). Many protein targets of redox reactions have been identified 
including receptors such as αIIbβ3 integrin, phosphatases such as SHP-1/2, 
PTEN and protein phosphatase-1α (PP1α), cytoskeletal components such as 
actin and signal transducers such as caspases, ras-related C3 botulinum toxin 
substrate 1 (Rac1), IκB kinase (IKK) and kelch like-ECH-associated protein 1 
(Keap1). Production of ROS mediates modulation of multiple signaling 
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pathways including activation of p-53, Ras, PI3-K and p38 MAPK signaling and 
modulation of gene transcription by NFκB, nuclear factor erythroid-derived-like 2 
(Nrf2), Egr-1 (Haddad, 2002a; Hainaut and Mann, 2001; Iiyama et al., 2006; 
Naughton et al., 2009; Pan et al., 2009). ROS signaling results in cellular 
functions such as proliferation and secretion of inflammatory cytokines (Iiyama et 
al., 2006) (Haddad, 2002b). On the other hand, hypoxia can result in migration of 
macrophages and DC and activation of transcription factors including HIF1α, 
HIF2α, activator protein-1 (AP-1), activating transcription factor-2/5 and Fos 
homolog B (Bosco et al., 2008; Haddad, 2002a). This dissertation elucidates a 
novel target downstream of redox signaling, the transcription factor IRF-8 and 
implicates the redox sensitive phosphatase SHP-1/2 in this regulation. 
Alox15 mice 
 Mice deficient in 12/15-LOX, Alox15 mice, have been developed by 
targeted disruption of exon 3 to generate an in-frame stop codon prior to the 
catalytic domain (Sun and Funk, 1996). Alox15 mice have been extensively 
studied in the context of inflammation. For instance, Alox15 mice were protected 
against atherosclerosis (Cyrus et al., 2001; George et al., 2001). This protection 
was associated with decreased ox-LDL production in Alox15 macrophages (Sun 
and Funk, 1996) and decreased IL-12p40 production in Alox15 atherosclerotic 
lesions (Zhao et al., 2002). Alox15 mice were also protected against 
inflammation caused by allergic asthma (Andersson et al., 2008; Hajek et al., 
2008) and acute lung injury (Zarbock et al., 2009). The attenuated inflammation 
was associated with decreased levels of the 12/15-LOX product 12(S)-HETE 
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(Zarbock et al., 2009). However, Alox15 mice exhibited exacerbated 
inflammation in a tumor necrosis factor transgenic model of arthritis (Kronke et 
al., 2009), which was associated with decreased levels of the anti-inflammatory 
12/15-LOX-mediated product, LXA4. Therefore, the signaling downstream of 
12/15-LOX depends on the production and context of specific 12/15-LOX-
generated products.  
 12/15-LOX promotes IL-12p40 production in macrophages. Alox15 
peritoneal macrophages but not bone marrow derived dendritic cells exhibited 
decreased levels of IL-12p40 in response to LPS and IFN-γ stimulation. This 
defect was associated with decreased levels of IRF-8 and NF-κB binding to the 
IL-12p40 promoter (Middleton et al., 2006a). Others also demonstrated that 
12/15-LOX contributes to inflammatory gene expression in macrophages 
(Dioszeghy et al., 2008). 12/15-LOX regulation of IL-12p40 and inflammatory 
gene transcription in macrophages has implications for inflammatory diseases in 
which macrophages play a predominant role. As stated previously, 12/15-LOX-
dependent IL-12p40 production contributed to the inflammatory milieu and 
disease progression of atherosclerosis (Zhao et al., 2002). Moreover, Alox15 
mice were defective in immunity to chronic toxoplasma gondii infection but not 
during acute infection (Middleton in press) highlighting the selective role of 12/15-
LOX and macrophages during chronic inflammation. In this dissertation, I will 
demonstrate that 12/15-LOX regulates IL-12p40 production in macrophages at 
least in part through ROS signaling.  
MPN in Alox15 mice 
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 In the course of studying Alox15 mice in the context of chronic 
inflammation, our lab made the unexpected finding that Alox15 mice exhibit 
increased mortality due to development of a CML- like MPN in about 10-15% of 
the mice over the course of a year. The majority of Alox15 mice remained 
asymptomatic and exhibited splenomegaly, basophilia, and an increased 
percentage of granulocytes in blood and spleen. Alox15 Gr1+ splenocytes 
exhibited increased proliferation and decreased cell death compared to wild-type. 
Addition of the 12/15-LOX product 12(S)-HpETE increased cell death in both 
Alox15 cells and the human K562 CML cell line (Middleton et al., 2006b).  
Asympomatic Alox15 myeloid cells also exhibited increased phosphorylation of 
the tyrosine kinase Akt, and decreased nuclear accumulation and transcriptional 
activity of tumor suppresssor IRF-8. Meanwhile, the moribund mice exhibited a 
MPD characterized by massive splenomegly, accumulated granulocytes in the 
bone marrow, spleen, blood and skin and the presence of myeloid blasts. This 
phase of disease was associated with the loss of IRF-8 gene expression 
(Middleton et al., 2006b). Because a proportion of Alox15 mice develop a MPN, I 
hypothesized that 12/15-LOX regulates myelopoieis. In this dissertation, I will 
demonstrate that 12/15-LOX does indeed regulate myelopoiesis and elucidate 
the mechanisms whereby this regulation occurs. 
12/15-LOX in Hematopoiesis 
 Although the relationship between fatty acid metabolism and inflammation 
in mature leukocytes has been extensively studied, little is known about the 
contributions of fatty acid metabolism to hematopoietic development. During 
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erythroid development in rabbits and humans, the 12/15-LOX products 15(S)-
HETE and 13(S)-HODE modulate membrane degradation, an important step in 
erythroid differentiation (Kuhn and Brash, 1990; van Leyen et al., 1998). However 
prior to my studies, the role of 12/15-LOX in murine erythroid development was 
unknown. 
 Little was previously known about the role of 12/15-LOX and its products 
in myeloid development. Addition of 12/15-LOX lipid products 12(S)-HETE and 
15(S)-HETE to cultures of human CD34+ cells decreased the numbers of 
granulocyte-macrophage colonies in methylcellulose assays (Desplat et al., 
2000). However the role of 12/15-LOX in granulocyte and monocyte 
differentiation has remained unexplored. Data presented in this dissertation 
demonstrate that 12/15-LOX promotes monocyte development. 
As stated earlier, previous studies in our lab demonstrated that 12/15-LOX 
is a novel suppressor of MPN (Middleton et al., 2006b). Approximately 15% of 
Alox15 mice develop a severe MPN over the course of a year. Moreover, the lipid 
mediators of 12-lipoxygenase are reduced in human CML (Stenke et al., 1991; 
Stenke et al., 1987; Takayama et al., 1983) implicating 12/15-LOX in the 
regulation of human disease as well. Although 12/15-LOX acts as a suppressor 
of myeloid leukemogenesis, its role in normal myeloid development was not 
previously known.  
ICSBP/IRF-8, a critical regulator of lineage specification and immunity, is 
regulated by 12/15-LOX. Our lab previously demonstrated that IRF-8 DNA 
binding and nuclear accumulation were compromised in Alox15 
33 
 
macrophages and splenocytes (Middleton et al., 2006a; Middleton et al., 2006b). 
This resulted in decreased IL-12p40 transcription in Alox15 macrophages 
(Middleton et al., 2006a) and in a CML-like myeloproliferative disorder in Alox15 
mice (Middleton et al., 2006b). IRF-8 was shown in these studies to be regulated 
by 12/15-LOX in part through phosphoinositide 3-kinase (PI3-K). PI3-K activity as 
measured by pAKT levels was increased in Alox15 BM-derived cells and 
inhibition of PI3-K resulted in increased nuclear accumulation of IRF-8 and 
restored gene transcription (Middleton et al., 2006b). Because 12/15-LOX 
regulates IRF-8 in mature myeloid cells, I hypothesized that 12/15-LOX also 
regulates IRF-8 in immature myeloid cells. Moreover, because IRF-8 is important 
to the development of multiple hematopoietic lineages, I hypothesized that 12/15-
LOX may also regulate hematopoiesis by promoting ICSBP/IRF-8 nuclear 
accumulation and transcriptional activity. 
ROS in Hematopoiesis 
ROS, which are functional by-products of 12/15-LOX activity (Conrad, 
1999), are known to regulate HSC function. Low levels of ROS maintained 
through interactions in the osteoblastic HSC niche are critical for LT-HSC 
function (Jang and Sharkis, 2007). The oxidative state of HSCs is also regulated 
in part by NAPDH-oxidases (Piccoli et al., 2007). However, the role of 
lipoxygenase-generated ROS has not yet been defined in HSC.  
Increased levels of ROS can signal through p38 MAPK to cause defective 
HSC quiescence and self-renewal. Treatment of normal bone marrow with 
buthionine sulfoximine (BSO), which increases ROS by inhibiting synthesis 
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of the anti-oxidant gluthathione, increased p38 MAPK specifically in HSC and 
inhibited the ability of HSC to reconstitute lethally irradiated mice (Ito et al., 
2006). Levels of ROS increased in HSC during serial transplantations and 
treatment with the anti-oxidant N-acetylcysteine (NAC) or with a p38 MAPK 
inhibitor extended the self-renewal ability of serial reconstituted HSC (Ito et al., 
2006). Deletion of the DNA repair enzyme ataxia telangiectasia mutated (ATM) 
increased levels of cellular ROS, decreased quiescence and increased p38 
MAPK activation in the HSC. This resulted in a defect of ATM-deficient HSC to 
reconstitute lethally irradiated mice. Treatment with a p38MAPK inhibitor 
(SB203580) restored HSC quiescence and function (Ito et al., 2006). ROS in 
HSC were also increased when members of the forkhead box subgroup O 
(FoxO) transcription factor family (FoxO1/3/4) were deleted. Similar to ATM-
deficient HSC, FoxO-deficient HSC exhibited increased levels of ROS, 
decreased quiescence and a defect in the ability to reconstitute lethally irradiated 
mice. Treatment with the anti-oxidant NAC restored HSC quiescence and 
function (Tothova et al., 2007). The perturbed HSC function associated with 
FoxO deletion was also associated with activation of p38 MAPK. Moreover, 
FoxO3a-deficient HSC exhibited similar defects as FoxO1/3/4-deficient HSC. 
FoxO3a-deficient HSC exhibited increased activation of p38MAPK and treatment 
with a p38MAPK inhibitor restored HSC function in this mouse model (Miyamoto 
et al., 2007). 
The tuberous sclerosis complex (TSC)-mammalian target of rapamycin 
(mTOR) pathway also functions in HSC to suppress ROS production and 
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promote HSC quiescence and self-renewal. When TSC was conditionally deleted 
in hematopoietic cells, the HSC exhibited increased proliferation and defective 
self-renewal. These defects were accompanied by an increase of ROS in the 
HSC in part by increasing mitochondrial biogenesis. Treatment with the anti-
oxidant NAC restored HSC function (Chen et al., 2008). Hence, accumulation of 
ROS negatively impacts HSC function and self-renewal in multiple mouse 
models. In this dissertation, I demonstrate that Alox15 HSC exhibit increased 
basal levels of ROS but decreased levels of ROS in response to AA that is likely 
12/15-LOX-dependent. The increased basal levels of ROS in Alox15 HSC may 
contribute to their defective self-renewal and quiescence.  
 ROS may also have effects on myeloid cell fate decisions. ROS mediate 
cytokine receptor signaling, including in response to GM-CSF. Addition of ROS in 
the form of hydrogen peroxide increased tyrosine phosphorylation of cytokine 
receptors and signal transducers while addition of anti-oxidants had the converse 
effect (Iiyama et al., 2006; Sattler et al., 1999). Moreover, ROS generated by 
dominant negative NF-κB inhibits granulocyte differentiation, which was restored 
by addition of an anti-oxidant (Nakata et al., 2004). However, this study did not 
examine the effects on mature monocyte development. In this dissertation, I 
demonstrate that ROS mediate monocyte development in Alox15 mice.  
Summary 
 In summary, in the following chapters I will describe novel functions for 
12/15-LOX in hematopoietic development. Because a percentage of Alox15 mice 
develop a myeloproliferative disorder, I hypothesized that 12/15-LOX 
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regulates hematopoietic development. To test this hypothesis, I characterized 
hematopoietic subsets in wild-type and Alox15 mice. I found that 12/15-LOX 
regulates HSC function and monocyte development. For my dissertation, I 
elucidated the mechanisms whereby this regulation occurs. An overview of my 
dissertation is shown in Figure 7. 
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EXPERIMENTAL METHODS 
Mice- C57BL/6 (B6) and Alox15 mice (backcrossed to B6 11 generations) 
purchased from Jackson Laboratories, were housed and bred in the animal 
facility of the Wistar Institute. Mice were used between 8-10 weeks of age prior to 
the onset of MPD except where explicitly stated. Congenic B6.SJL mice were 
obtained from Taconic or NCI. All animal procedures were approved by Wistar 
Institute institutional care and animal use committee.  
Hematologic analysis- Whole blood obtained via submandibular bleeding diluted 
with 1% PBS/PBS with 5 µL of 0.5 M EDTA. Blood was analyzed on an 
Advia2120 hematology analyzer in the mouse mode (Siemens Healthcare 
Diagnostics).  
Fetal liver isolation-Two female mice and 1 male mouse were placed in a cage 
overnight. Mice were then separated by sex and pregnant mice were sacrificed 
14 days later to isolate fetal liver from day 14.5 embryos. 
Macrophage isolation-To generate bone marrow derived macrophages, bone 
marrow from wild-type and Alox15 mice were isolated from the long bones. Cells 
were subject to RBC lysis using ammonium chloride and were cultured at 1x106 
cells per ml, in 10 ml of 10% L292 supernatant in RPMI containing 10% fetal calf 
serum (FCS), 50µM β-Mercaptoethanol, 1% penicillin, streptomycin and 
fungizone on untreated 10cm2 tissue culture plates. After 5 days, non-adherent 
cells were washed away and purity was checked by flow cytometry. Cells were at 
least 85-90% macrophages by F4/80+ staining and flow cytometric analysis. 
To isolate thioglycolate-elicited macrophages, B6 and Alox15 mice were 
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injected intraperitoneally with 2ml sterile 3% Brewer’s thioglycollate broth (Sigma-
Aldrich). Four days later macrophages were isolated peritoneal cavity with PBS. 
Cells were plated for 2 hours to overnight in 10% FCS in RPMI containing 50µM 
β-Mercaptoethanol, 1% penicillin, streptomycin and fungizone. Non-adherent 
cells were washed away. The remaining cells were at least 90% pure by F4/80+ 
staining and flow cytometric analysis.  
Flow cytometry- Single cell suspensions were prepared from thymus, spleen, 
fetal liver and BM isolated from tibia and fibulas. RBC were lysed using 
ammonium chloride except for erythroid progenitor analysis. 
Immunocytochemistry reagents were obtained from the following sources: cKit, 
Invitrogen; CD34, CD45.1, Biolegend; CD3, IgM, Gr1, streptavidin-conjugates, 
BD Bioscience; all others, eBioscience. Differentiated cells were depleted with a 
cocktail of antibodies directed against: Gr-1, B220, CD3, IL-7Rα, Ter119, NK1.1, 
Mac1 and CD11c; anti-IL7Rα was omitted when analyzing CLP, ETP, DN2 and 
DN3. Cells were resuspended for staining in 1%BSA/PBS and blocked for 
nonspecific staining using murine IGG (Jackson ImmunoResearch) for 5 minutes 
room temperature before addition of antibodies. Cells were stained for 30 
minutes at 4C and washed with PBS. Secondary antibody staining was in 
phosphate buffered saline (PBS) for 30 minutes at 4C. Cells were analyzed by 
flow cytometric analysis on a FACS Calibur or LSR II using Flowjo software 
(Treestar).  
Cell cycle analysis- Bone marrow was isolated and stained at 1x106 cells/ml in 
2% FCS RPMI with 10 µg/ml Hoechst 33342 at 37C incubator for 45 minutes 
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followed by addition of 300 ng/ml PyroninY (Sigma-Alrich) for an additional 45 
minutes. Cells were then washed with cold PBS and kept at 40C for subsequent 
multicolor flow cytometric analysis to identify progenitor populations. In some 
experiments, bone marrow was treated for 45 minutes or overnight with 
increasing concentrations of 12(S)-HETE or 15(S)-HETE (Cayman Chemical). 
AnnexinV and TUNEL staining- For AnnexinV staining, cells were stained for 
multicolor flow cytometry prior to incubation with 5 µl AnnexinV-FITC (Invitrogen) 
in 100 µl AnnexinV staining buffer for 10 minutes at room temperature after which 
400 µl additional staining buffer was added. 
 In situ staining kit for Terminal deoxynucleotidyl transferase-mediated dUTP 
nick end labeling (TUNEL) was obtained from Roche. Staining was performed 
according to manufacturer’s protocol. Treatment with DNAse was used as a 
positive control while fluorescence minus one (FMO) (without fluorescein-dUTP) 
was used as a negative control. 
Bone marrow reconstitution and 5-FU assays -Recipient mice were irradiated 
with 1000 rads of γ irradiation from a Cesium J. L. Sheppard Mark irradiator. 
Mice were transplanted with 1.8x106 test: 2x105 competitor BM cells (9:1), 
2x105:2x105 competitor BM cells (1:1),  1x106 E14.5 fetal liver cells: 0.5x106 
competitor BM cells (2:1) and 0.5x106 E14.5 fetal liver cells: 0.5x106 competitor 
BM cells (1:1) for competitive reconstitution assays and 1x106 BM cells for 
noncompetitive and serial reconstitution assays. Mice were injected i.p. with 200 
mg/kg 5-FU (Roche) to determine self-renewal ability. 
Cell separation-Lin-cKit+ cells were obtained using MACS separation kit 
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(Miltenyi-biotech). Briefly, cells were resuspended in 40 µl MACS Buffer (0.5% 
BSA 2 mM EDTA PBS pH 7.2) per 107 cells and 10 µL of lineage antibodies were 
added per 107 cells. Cells were incubated for 10 minutes at 4oC prior to addition 
of 30 µL MACS buffer per 107 cells and 20 µL anti-biotin microbeads. Cells were 
then incubated for an additional 15 minutes prior to washing with PBS. Cells 
were resuspended with 500 µL MACS buffer per 108 cells and the negative 
fraction was obtained on LS columns. For some experiments, cKit microbeads 
were used subsequent to the Lin- purification. Cells were counted and 
resuspended in 80µl MACS buffer per 107 cells and 20 µL cKit microbeads were 
added per 107 cells. Cells were incubated for 15 minutes prior to washing and the 
positive fraction was collected on MS columns. In all experiments, purity was 
checked using flow cytometric analysis and determined to be at least 90% pure. 
Immunoblotting- Nuclear extracts were prepared using Nucbuster kit (EMB 
Biosciences) from Lin-cKit+ cells pooled from 3 mice and from bone marrow-
derived macrophages. MPER was used to obtain total (cytoplasmic and nuclear) 
cell lyates. Lysates were normalized to total protein using Bradford assay 
(Pierce) and resolved by 7.5% SDS PAGE, transferred to PVDF membranes, 
and immunoblotted with antibodies specific for ICSBP/IRF-8, Dab2, Rb, 12/15-
LOX (Santa Cruz Biotechnology) and β-catenin (BD Bioscience). Peroxidase-
conjugated secondary antibodies were obtained from Jackson Immunoresearch.  
ROS and lipid analysis- ROS levels were analyzed on LSK enriched by cell 
sorting and on BMM by loading with 10 µM CM-H2DCFDA (Invitrogen) in the 
presence (LSK) or absence (LSK, BMM) of 10 µM AA (Cayman Chemical) 
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(LSK) for 30 min at 37°C. Cells were then analyzed by flow cytometry. For lipid 
analysis, BM, Lin- enriched cells and BMM were loaded for 30 minutes with 10 
µM AA (Cayman Chemical), the supernatants were extracted and analyzed by 
stable isotope dilution normal phase chiral liquid chromatography coupled with 
electron capture atmospheric pressure chemical ionization/mass spectrometry. 
Cell sorting and quantitative-PCR-BM cells from 3-5 mice were pooled, stained 
and sorted on an Aria cell sorter at the University of Pennsylvania or Wistar 
Institute flow cytometry facility. mRNA was isolated using RNeasy microRNA kit 
(Qiagen) and cDNA synthesized using reverse transcriptase. Quantitive real time 
PCR was performed with Syber green master mix in an ABI 7000 cycler (Applied 
Biosystems) and normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) levels. Primer sequences were designed using Primer Express 
(Applied Biosystems).  
Primer Sequences 
Gapdh (forward) 5′−G A C G G C C G C A T C T T C T T G T and (reverse) 5′−C 
A C A C C G A C C T T C A C C A T T T T-3′; β- actin, (forward) 5′−T C A G C A 
A G C A G G A G T A C G A T G -3′ and (reverse) 5′−A A C A G T C C G C C T 
A G A A G C A C T T-3′; Icsbp/Irf8 (forward) 5′T G G G C A G T T T T T A A A G 
G G A A G T T-3′ and (reverse) 5′-A C A G C G T A A C C T C G T C T T C C A -
3′; 12/15- Lox (forward) 5′-A C C C C A C C G C C G A T T T T  and (reverse) 5′-
A G C T T C G G A C C C A G C A T T T; Dab2(forward) 5′−G G C C A C A C C 
G C C T C A A- 3′(reverse) 5′−A G C G T C A C T G G G A A T G T C C T T-3′; 
Nf1 (forward) 5′−G G T A T G G A C A C A G G A C C T C T A G G A T-3′ 
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and (reverse) 5′−C T G C G G G T A C C A T G A A G C A-3′; Blimp1 (forward) 
5′−G G A G G A T C T G A C C C G A A T C A-3′ and (reverse) 5′−T C C T C A 
A G A C G G T C T G C A T T G-3′; p15Ink4b(forward) 5′−T G G G T G G G T G 
C A G T C A G T A C-3′ and (reverse) 5′−T C C C A T T T A G C C T G T G G A 
T C A-3′; Hes-1 (forward) 5′−T C A G C G A G T G C A T G A A C G A-3′ and 
(reverse) 5′−T G C G C A C C T C G G T G T T A A C-3′; Bmi (forward) 5′−T T C 
C G C C C G C T C A G A T C-3′ and (reverse) 5′−C G A T G C A T T T C T G C 
T T G A T A A A A-3′; Hoxb4 (forward) 5′−G A A G G A A G C A A G A A A A G 
G A G G A A-3′ and (reverse) 5′−G A T T A A A G A T G A A G C C T G G A T C 
C A T-3′; Gfi1 (forward) 5′−T G C T C C G A G T T C G A G G A C T T-3′ and 
(reverse) 5′−C A G A G A G C G G C A C A G T G A C T T-3′; PU.1 (forward) C 
C G G A T G T G C T T C C C T T A T C and (reverse) T C T A C C C T C C T C 
C T C A T C T G A; C/EBPα (forward) G A C C A T T A G C C T T G T G T G T 
A C T G T A T G and (reverse) T G G A T C G A T T G T G C T T C A A G T T; 
Egr-1 (forward) C C A T G A A C G C C C A T A T G C T T and (reverse): G C T 
C A T C C G A G C G A G A A A A G 
Methylcellulose assays- 1.5x105 splenocytes, 1.5x104 bone marrow cells, 500 
sorted LSK and CMP and 1000 GMP and MEP were plated in methylcellulose 
containing IL-3, IL-6, SCF and EPO (M3434, Stem Cell Technologies). In other 
methylcellose assays, 5x105 wild-type or Alox15 bone marrow cells were plated 
in methylcellulose (M3234, Stem Cell Technologies) after addition of 10 ng/ml M-
CSF, G-CSF, GM-CSF or IL-3 (Peprotech). After 10 days, colonies were 
enumerated using light microscopy in a blinded fashion. In some assays, 1 
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µM 12(S)-HETE (Cayman Chemical), 10 µM or 50 µM NSC-87877 (EMD 
bioscience) or 0.025 µM BSO (Sigma) were added to the methylcellulose at the 
time of plating.  
Rapamycin treatment- Rapamycin (LC, laboratories) was dissolved in absolute 
ethanol into 50 mg/ml stock and then further diluted in 5% Tween-80 (Sigma) and 
5% PEG-400 (Sigma).  Mice were injected intraperitoneally with 4 mg/kg 
rapamycin or vehicle control in a 200 µl volume daily for 7 days. 
Retroviral Studies- MigR retrovirus was obtained from Dr. W. Pear (University of 
Pennsylvania). Mutated nondegradable Beta-catenin MSCV was obtained from 
Dr. T. Reya (Duke University). 12/15-LOX in the MigR retroviral construct was 
constructed by introducing a Bgl II site using PCR amplification of a plasmid 
containing 12/15-LOX (C. Funk) followed by subcloning into Topo vector 
(Invitrogen). The MigR vector and the 12/15-LOX Topo plasmid were digested 
overnight with Bgl II and XhoI, purified and ligated. Sequence of 12/15-LOX was 
verified by sequencing (University of Pennsylvania).  
 To make the retroviral particles, 293T cells were plated at 2x106 cells/plate 
into 6 cm plates in 3 ml. The next day, the media was replaced with warm media 
containing 25 mM chloroquine. The transfection cocktail was prepared in 1.7ml 
eppendorf tubes in 500 µl total volume in sterile water: 50 µL 2.5 M CaCl2, 5 µg 
pCL-Eco packaging vector (Imgenex), 10 µg retroviral plasmid. 500 µL HEPES-
buffered saline HeBS (2X: 50 mM HEPES, 10 mM KCl, 12 mM Dextrose, 280 
mM NaCl, 1.5 mM Na2HPO4 at pH 7.1 filtered and frozen aliquots at -20oC) was 
added drop-wise with a 1 ml serological pipette and then bubbled and 
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vortexed for 10 seconds each. The cocktail was slowly added to the side of the 
dish. After 5-7 hours, cells were washed and medium replaced. Medium was 
replaced again the following day. At 48 hours post-transfection, viral particles 
were isolated from the supernatant, filtered through a 0.45 µM syringe and 
aliquots stored at -80oC. Titer was checked on 3T3 cells grown at 1x106 overnight 
in 6 cell plates. 100 µL supernatant and 2 µg/mL polybrene was added and titer 
checked for GFP expression by flow cytometry 48-72 hours post-transduction. 
 For retroviral transduction, B6 and Alox15 E14.5 fetal liver cells were 
isolated and stimulated with 50 ng/ml SCF, 10 ng/ml IL-3 and IL-6 (Peprotech) at 
2-3x106 cells/ml in 4 ml 20% FCS RPMI in 6 well plates. After overnight 
incubation, 0.5-1 ml was taken, spun and replaced with 0.5-1 ml retroviral 
supernatant and 4 µg/ml polybrene (Sigma) was added. Cells were spun for 90 
minutes at 2750 rpm and then put in an incubator overnight. The next day, the 
transduction procedure was repeated. Fetal liver cells were determined to be 
retrovirally tranduced by the expression of GFP in a percentage of the cells at 
day 3 in culture. Cells were at least 30% GFP+. On either day 2 or day 3, cells 
were washed 3X, counted and at least 1x106 cells were injected via tail vein in 
200 µl PBS into lethally irradiated mice (900 rads). For sublethal irradiation, 400-
700 rads were used. 
Statistical Analysis- One-way ANOVA, t-tests, or Mann-Whitney were applied 
using Graphpad Prism software or Excel as indicated for each data set. Results 
in which p<0.05 were considered statistically significant for all tests 
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CHAPTER 1: Alox15 mice exhibit alterations in hematopoietic 
compartments 
 Hematopoiesis is the process whereby all the cells of the immune system 
develop. It is a tightly regulated process orchestrated by a balance of 
transcription factor and cytokine signaling that results in defined numbers of 
blood cell populations including lymphoid, erythroid, and myeloid cell lineages. 
HSCs are the only cells with both the ability to self-renew and to differentiate into 
all blood cell types. As cells further differentiate they become more limited in their 
differentiative capacity. Dysregulated hematopoiesis can result in leukemias, 
anemias or immunodeficiencies. Therefore, it is important to elucidate pathways 
that contribute to normal hematopoiesis. Although much is known about 
transcription factors that regulate cell fate decisions during hematopoietic 
development, less is known about signaling pathways that govern hematopoietic 
cell specification. 
 Although fatty acid metabolism has been extensively studied in the context 
of chronic inflammation mediated by hematopoietic cells, the role of fatty acid 
metabolism in general during hematopoietic development is not well understood. 
In the process of studying the role of 12/15-LOX-mediated fatty acid metabolism 
in the context of chronic inflammation, our lab discovered that a proportion of 
Alox15 mice, which lack 12/15-LOX, developed a CML-like disease over the 
course of a year. Moreover, the majority of Alox15 mice which lacked the CML-
like disease were referred to as “asymptomatic” and exhibited an increased 
percentage of Mac1+Gr1+ cells in the blood, spleen and bone marrow (BM) 
47 
 
(Middleton et al., 2006b). However, other hematopoietic compartments within 
Alox15 mice were not studied in depth. Because Alox15 mice exhibited an 
increased percentage of granulocytes and developed a leukemia, I hypothesized 
that 12/15-LOX regulates hematopoiesis. To formally test this hypothesis, I 
characterized the hematopoietic subsets in wild-type and Alox15 mice. This 
chapter describes the multiple hematopoietic defects in Alox15 mice which 
demonstrates that 12/15-LOX does indeed regulate hematopoiesis.  
Alterations in WBC compartment 
 To establish the impact of 12/15-LOX deletion on the peripheral 
hematopoietic compartment, we performed hematologic analysis of peripheral 
blood from “asymptomatic” 12-15 week old Alox15 and B6 mice. Alox15 mice 
exhibited a lower white blood cell (WBC) count, largely attributable to a reduction 
in lymphocytes and monocytes. Although the number of eosinophils and 
neutrophils were similar, they accounted for a greater percentage of total cells in 
Alox15 mice. The absolute number of basophils in asymptomatic Alox15 mice 
was increased as noted previously (Figure 8A; (Middleton et al., 2006b).  
To dissect the reduction in lymphocytes in Alox15 mice, we examined 
mature lymphoid populations in the spleen and lymphoid development in BM and 
thymus. The reduction in mature lymphocytes was mainly attributed to a 
reduction in B cells in the spleen (Figure 8B). Moreover, B cell development in 
the BM was defective in Alox15 mice. Although the percentage of earliest B 
lineage progenitors, including LSK (Lin-Sca1+cKit+), common lymphoid 
progenitors (CLP: Lin-IL-7Rα+cKitloSca1lo) and preproB (B220+CD43+HSA-
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CD19-) cells were similar between wild-type and Alox15, the percentage of proB 
(B220+CD43+HSA+CD19+) and preB (B220+CD43-IgM-CD19+) cells were reduced 
in Alox15 BM (Figure 8C). We also observed a less dramatic but significant 
defect in T cell development. Double-positive thymocytes (CD4+CD8+) were 
decreased in Alox15 compared to B6, but early thymic progenitors (ETP: Lin-
CD25-cKit+), DN2 (Lin-CD25+cKit+) and DN3 (Lin-CD25+cKit-) were similar (Figure 
8D).   
We next determined whether the defects in the WBC compartment were 
also defective in younger (6 week), and older (26-30 weeks) mice using 
hematologic analysis of peripheral blood. Indeed the alterations in WBC, 
lymphocytes, monocytes and basophils were detected at multiple ages (Figure 
9). Moreover, hematologic analysis of the subset of Alox15 mice exhibiting a 
CML-like MPN, demonstrated increased numbers of WBC compared to 
asympomatic Alox15 mice between 26-30 weeks of age. This increase was due 
primarily to an increase in neutrophils, which confirms the CML-like MPD in these 
mice (Figure 9). 
12/15-LOX regulates RBC development 
As 12/15-LOX regulates erythroid development in rabbits and humans, we also 
investigated whether 12/15-LOX regulates murine erythroid development. Alox15 
mice exhibited a decrease in red blood cells (RBC) and a concomitant increase 
in reticulocyte number at 12-15 weeks of age. Moreover, hemoglobin (HGB) was 
decreased while mean cell volumes (MCV) of the RBC were increased, indicating 
that Alox15 mice developed a macrocytic anemia 
49 
 
50 
 
51 
 
(Figure 10A). *** 
Because RBCs were decreased in Alox15 mice, we determined the 
percentage of erythroid progenitors in the BM and the spleen using Ter119 and 
CD71 (transferin receptor) erythroid markers. Despite the decrease in mature 
RBC, Alox15 erythroid progenitors were expanded, particularly in the spleen, the 
major site of stress erythropoiesis in mice (Figure 10B). Both proerythrocytes 
(CD71+Ter11lo) and erythrocyte progenitors (Ter119hi) were expanded. To 
determine at which point the defect in RBC development occured, I compared 
the frequency of B6 and Alox15 cells in erythroblasts fractions A, B and C using 
CD71 and forward scatter after gating on the Ter119+ progenitors. As 
erythroblasts develop they exhibit high forward scatter (size) and elevated levels 
of CD71 (transferrin receptor), which participates in iron transport (Fraction A). 
As the erythroid progenitors mature, they uptake iron and condense their 
membranes leading to decreased forward scatter (Fraction B). Eventually the 
erythroid cells are condensed and lose CD71 expression (Fraction C). Alox15 
BM and spleen had increased fraction A, and the Alox15 spleen exhibited an 
increase in fraction B compared to wild-type. However, there was a comparable 
percentage of cells in fraction C between wild-type and Alox15 BM and spleen 
suggesting a block in erythroid differentiation at this stage (Figure 10C). The 
defect in RBC development likely occurs at the erythroblast B-C transition. 
These data are consistent with the reported expansion of splenic red pulp 
in Alox15 mice (Middleton et al., 2006b). Therefore, I examined H&E stained 
splenic sections from wild-type and Alox15 mice to identify whether the 
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expansion of the red pulp was due to the presence of erythroid progenitors.  
Indeed, Alox15 spleens contained an abundance of erythroid progenitors, which 
are identified as darkly stained cells, that are relatively absent in wild-type 
spleens (Figure 11A-B). The presence of erythropoiesis was also demonstrated 
by megakaryocytes, which were observed in the spleens of Alox15 but not wild-
type (Figure 11C). In Alox15 mice with MPN, there was a complete loss of 
splenic architecture and accumulation of mature and immature granulocytes as 
previously reported (Figure 11D) (Middleton et al., 2006b). 
Alterations in RBC parameters were defined in both young and old mice 
by hematologic analysis. Both young (6 week) and older (26-30 week) Alox15 
mice exhibited decreased RBC and HCT. In addition, older Alox15 mice (26-30 
week) exhibited a decrease in platelet count (Figure 12). We also determined the 
cellular subsets in the blood of the approximately 15% of Alox15 mice over the 
course of a year that were moribund (Middleton et al., 2006b). This analysis 
indicated there was a severe decrease in RBC and hematocrit (HCT) as the 
Alox15 mice progressed from the asymptomatic syndrome to the more 
aggressive disease (Figure 12). 
No significant hematopoietic defects in Alox15 heterozygous mice 
 We also characterized the hematopoietic compartment of Alox15 
heterozygous mice. First we determined that the splenocytes of heterozygous 
Alox15 mice express roughly half as much 12/15-LOX as wild-type and hence 
12/15-LOX is expressed in a gene dose-dependent manner (Figure 13A). 
However, based on hematological analysis of peripheral blood subsets, there 
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 were no significant defects in the hematopoietic compartment (Figure 13B-C). 
This may be due to small numbers (n=4) and variability in age of the mice (5-12 
weeks). Nonetheless, no significant differences were detected in WBC (Figure 
13B) or RBC (Figure 13C) parameters.  
Defects in Alox15 mice are cell-autonomous 
To determine whether the defects in Alox15 mice were cell-autonomous, 
we performed adoptive transfer studies to define whether the phenotype was 
inherent to BM-derived cells and/or dependent on the host environment. B6 or 
Alox15 donor BM cells were engrafted into lethally irradiated congenic wild-type 
recipients. At 16 weeks post-engraftment, recipient mice reconstituted with 
Alox15 cells had decreased total WBC, lymphocytes and RBC in peripheral blood 
compared to mice reconstituted with B6 BM (Figure 14A), analogous to the 
defects observed in cells from Alox15 mice. Conversely, when congenic wild-type 
(B6.SJL) BM was used to reconstitute B6 or Alox15 mice, there were no 
differences in total or differential white blood counts (Figure 14B). These data 
indicate that 12/15-LOX regulates hematopoiesis in a cell-autonomous manner.  
Implications 
Through the comparison of peripheral hematopoietic subsets in wild-type 
and Alox15 mice, we demonstrate that 12/15-LOX regulates multiple 
hematopoietic subsets in a cell-autonomous manner. However, although we 
demonstrate the the phenotype of the blood cell subsets of track with the 
genotype of the reconstituted bone marrow, it is possible that a subset of bone 
marrow cells function in a paracrine manner to regulate blood cell 
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development. We more definitely demonstrate that the defect in blood cell 
development is cell-intrinsic hematopoietic stem cells using competitive 
reconstitution assays in Chapter 2 of this dissertation. 12/15-LOX regulates T cell 
differentiation at the DP stage, B cell differentiation at the propreB cell stage, 
RBC generation, monocyte number and limits the number of basophils (Figure 
15). The presence of multiple hematopoietic defects in the Alox15 mice suggests 
that 12/15-LOX may regulate a common progenitor such as the hematopoietic 
stem cell. The role of 12/15-LOX in hematopoietic stem cell function will be 
discussed in Chapter 2. 
Although these data suggest that 12/15-LOX may regulate a common 
progenitor such as the HSC, it is also possible that 12/15-LOX may 
independently directly regulate multiple hematopoietic subsets. These 
possibilities are not mutually exclusive and our data as well as previous findings 
suggest that both these possibilities do in fact simultaneously occur. Our data 
imply that 12/15-LOX may possibly regulate development of B and T 
lymphocytes, erythrocytes, and monocytes by distinct mechanisms by which it 
regulates HSC function. 
The mechanism whereby 12/15-LOX regulates B and T cell development 
remains to be elucidated. Interestingly, 12/15-LOX had not been previously 
shown to regulate lymphoid cell populations though its products were found in 
the thymus (Harizi et al., 2008). Interestingly, IRF-8, which we demonstrated is 
regulated by 12/15-LOX, had been shown to regulate B cell development at the 
same stage of development that is defective in Alox15 mice (pro-preB cell 
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stage) (Lu et al., 2003). However, whether 12/15-LOX regulates B cell 
differentiation through IRF-8 is currently unknown and is a potentially interesting 
future direction. 
 The defect in late stage erythroid differentiation in Alox15 mice is in 
concordance with previous observations that a functional homolog of 12/15-LOX, 
15-LOX, and its specific products, 15(S)-HETE and 13(S)-HODE, in other 
species regulate reticulocyte maturation by modulating membrane degradation 
(Kuhn and Brash, 1990; van Leyen et al., 1998). 12/15-LOX had not been 
previously shown to regulate RBC development in mice and this is the first study 
that establishes its role in murine erythroid cell differentiation. To more fully 
understand the development of the macrocytic anemia in Alox15 mice, it would 
be an interesting future direction to elucidate the mechanism whereby 12/15-LOX 
regulates murine reticulocyte maturation. 
There were decreased blood monocytes in Alox15 mice suggesting that 
12/15-LOX may regulate monocyte development and myelopoiesis. The role of 
12/15-LOX in myeloid cell development is of interest because of the potential 
implications for CML and will be addressed further in Chapter 3 of this thesis. 
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 CHAPTER 2: 12/15-LOX is a critical regulator of LT-HSC self-renewal 
 The presence of multiple hematopoietic defects in Alox15 mice, detailed in 
Chapter 1, suggests two possibilities, either of which are plausible and not 
necessarily mutually exclusive. The first possibility is that 12/15-LOX regulates 
multiple stages of hematopoiesis independently. The second possibility is that 
12/15-LOX regulates a common hematopoietic progenitor such as HSC. The 
data presented in this and subsequent chapters demonstrate that both these 
possibilities occur. Specifically, I will present data in Chapter 3 which 
demonstrate that 12/15-LOX drives myelopoiesis by promoting ICSBP/IRF-8 
nuclear accumulation through redox signaling. In this chapter, I will present data 
which demonstrate that 12/15-LOX regulates HSC function and self-renewal in 
associated with modulation of canonical Wnt signaling.  
 The signaling pathways that govern the complex processes of HSC 
function are not completely understood. HSCs are relatively rare yet must 
produce billions of new cells daily and be able to adjust their output to respond to 
environmental stresses such as infection, chemotherapy, blood loss, injury, etc. 
To accomplish this, HSCs must divide asymmetrically by balancing self-renewal 
and differentiation. Skewing of asymmetric division results in defective HSC 
function. Decreases in numbers, alterations in the balance of asymmetric division 
and increased proliferation decreases the ability of HSC to function (Ficara et al., 
2008; Nemeth et al., 2006; Passegue et al., 2005). Although much is known 
about transcription factors that regulate these processes, such as Gfi-1, Bmi-1, 
Hox4b and Pu.1 (Hock et al., 2004; Iwama et al., 2004; Iwasaki et al., 2005; 
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Sauvageau et al., 1995), little is known about the signaling pathways that 
regulate HSC function. Canonical Wnt signaling is one known pathway that 
regulates HSC function by maintaining quiescence and initiating a self-renewal 
program of gene transcription (Fleming et al., 2008; Zhao et al., 2007; Luis et al., 
2009). In this chapter, I determine that 12/15-LOX is a novel regulator of 
canonical Wnt signaling which in turn may regulate HSC function by maintaining 
quiescence and self-renewal.  
Products generated by 12/15-LOX have been implicated in hematopoiesis. 
ROS, which are generated as a product of 12/15-LOX fatty acid metabolism, can 
impair HSC function by ROS-dependent regulation of the p38 MAPK pathway (Ito 
et al., 2006). Moreover, 12/15-LOX generated lipid products, 12(S)-HETE and 
15(S)-HETE, can inhibit differentiation of human CD34+ hematopoietic 
progenitors in methylcellulose assays (Desplat et al., 2000). However, a role for 
12/15-LOX per se has not been previously established in hematopoietic 
development and HSC function.  
 In this chapter, I define 12/15-LOX as a critical regulator of LT-HSCs. 
12/15-LOX regulates HSCs by promoting quiescence and self-renewal. Defective 
HSC function in Alox15 mice is associated with defects in select products of 
12/15-LOX including 12/15-LOX-generated ROS, 12(S)-HETE and 13(S)-HODE. 
12/15-LOX regulates nuclear ICSBP/IRF-8 accumulation in hematopoietic 
progenitors, which results in altered expression of ICSBP/IRF-8 target genes, 
including increased production of Dab2, a negative regulator of canonical Wnt 
signaling. Consequently, canonical Wnt signaling measured by its 
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downstream mediator, β-cantenin, is disrupted in Alox15 progenitors. Thus, we 
have defined 12/15-LOX as a novel regulator of LT-HSC function and canonical 
Wnt signaling. 
Alox15 mice exhibit a primary defect in HSC function  
To test the possibility that 12/15-LOX regulates HSC function, we needed 
to determine expression of 12/15-LOX in HSC. Using real time PCR analysis, we 
determined that 12/15-LOX mRNA was expressed in wild-type HSC isolated by 
cell sorting (Figure 16A). Moreover, 12/15-LOX protein was expressed in B6 (but 
not Alox15) Lin-cKit+ hematopoietic progenitors by immunoblot (Figure 16B).  
HSC function can be assessed by the ability to reconstitute the 
hematopoietic compartment of a lethally irradiated animal. Competitive 
reconstitution experiments, in which BM from control and experimental mice are 
mixed with wild-type BM and injected into lethally irradiated mice, are based on 
two assumptions: that HSC numbers and homing of the HSCs are similar 
between control and experimental BM cells. LSK were present in similar numbers 
in B6 and Alox15 BM (Figure 16C). Moreover, B6 and Alox15 BM cells homed 
with comparable efficiency to both normal and lethally irradiated recipient BM 
(Figure 16D). It was therefore appropriate to proceed with competitive 
reconstitution assays.  
To elucidate whether 12/15-LOX regulates early hematopoietic 
progenitors such as the HSC, we set up competitive reconstitutions in which B6 
or Alox15 BM cells (CD45.2) were mixed 9:1 with wild-type competitor B6.SJL 
BM cells (CD45.1) and engrafted into lethally irradiated B6.SJL recipient 
65 
 
66 
 
mice. Reconstitutions were monitored by bleeding the recipient mice every four 
weeks and analyzing the frequency of CD45.2 cells, which were derived from B6 
or Alox15 BM cells, amongst the total CD45+ population (Figure 17). At all time-
points post-reconstitution, the contribution of Alox15-derived total CD45+ cells, T 
cells, B cells and granulocytes were dramatically reduced compared to the 
contribution of B6 donor-derived cells (Figure 18A). After 16 weeks, BM was 
isolated and analyzed for progenitor subsets. Alox15 HSC were at a profound 
disadvantage compared to B6-derived HSC under competitive conditions as 
evidenced by a marked reduction in the proportion of Alox15-derived HSC 
compared to B6-derived HSC in recipient mice (Figure 18B). In addition to the 
HSC compartment, we also examined the contribution of B6 and Alox15 cells to 
B, T and myeloid cell development by gating on CD45.2. In addition to the defect 
in HSC, Alox15-derived cells exhibited additional defects at later stages of 
differentiation similar to those described in Chapter 1 (Figure 19). There was a 
further bias toward competitor-derived cells within B cell and T cell compartments 
compared to Alox15-derived HSC (Figure 19A-B). Moreover, the defect in more 
mature Alox15-derived cells was evident as early as four weeks following 
reconstitution in the blood, when cells were derived from more differentiated 
progenitors rather than the HSC (Figure 18A). 
Additional competitive reconstitution assays using B6 and Alox15 BM 
mixed 1:1 with congenic competitor cells demonstrated that limiting numbers of 
Alox15 BM resulted in a further decrease in Alox15-derived HSC during 
competitive reconstitution assays (Figure 20). 
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We also performed competitive reconstitution assays with Alox15 heterozygous 
cells. Similar to the lack of blood cell defects in Alox15 heterozygous mice 
(Chapter 1), HSCs from Alox15 heterozygous mice were not defective during 
competitive reconstitution assays compared to wild-type (Figure 21). Importantly, 
however, Alox15 HSCs were defective compared to Alox15 heterozygous HSC 
(Figure 21). 
Defect in Alox15 HSC is primary 
Multiple hematopoietic defects are present in Alox15 mice as described in 
Chapter 1, including lymphocytes, monocytes and RBCs. Rather than a primary 
defect in HSCs, it is possible that the reduced function of Alox15 HSCs is caused 
by their need to continually replenish the more mature hematopoietic 
compartments. Nonetheless, as the competitor cells provided a virtually normal 
hematopoietic compartment during competitive reconstitution assays, these data 
indicate that the defect in Alox15 HSCs was primary rather than secondary to 
abnormalities in hematopoietic cells at later stages of differentiation. However, to 
formally exclude the possibility that the defect in Alox15 HSCs was secondary to 
later hematopoietic defects, we repeated the competitive reconstitution assays 
with E14.5 fetal liver cells. Importantly, we found that Alox15 E14.5 fetal livers 
were similar to B6 based on H&E staining and by flow cytometric analysis of 
hematopoietic subsets and exhibited no overt phenotype (Figure 22A-B). In the 
competitive reconstitution assays, B6 and Alox15 fetal liver cells were mixed 2:1 
with normal congenic bone marrow to ensure readout of fetal liver-derived HSC 
function in the context of a normal hematopoietic compartment. Even under 
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these conditions, the contribution of Alox15-derived cells to the blood cell 
populations was significantly reduced compared to B6 at all times post-transfer 
into lethally irradiated congenic recipient mice (Figure 22C). Moreover, Alox15-
derived LSK and CD34-Flt3-LSK cells in the BM were significantly reduced 
compared to wild-type (Figure 22D). These experiments were also conducted 
with fetal liver cells mixed 1:1 with wild-type congenic competitive BM cells with 
similar results (Figure 23). These data effectively demonstrate that the defect in 
Alox15 HSCs is not secondary to defects in mature hematopoietic subsets. 
Rather, 12/15-LOX directly regulates HSC function.  
12/15-LOX regulates numbers, proliferation and function of LT-HSC  
We further compared the distribution of HSCs within the LSK population of 
B6 and Alox15 mice (Wilson et al., 2007; Wilson et al., 2008). Interestingly, 
Alox15 BM had a decreased percentage of primitive dormant LT-HSC (CD34-
CD150+CD48-Flt3-LSK) and an increased percentage of more differentiated 
MPP1 (CD34+CD150+ CD48+Flt3-LSK) compared to B6 (Figure 24A). The LT-
HSC population is highly enriched for HSC function and quiescent cells while the 
more differentiated cells are highly proliferative and have decreased capacity to 
self-renew. These data suggest that 12/15-LOX regulates the most primitive LT-
HSCs. 
To determine whether the defect in Alox15 HSCs in the BM competitive 
reconstitution assays was due to 12/15-LOX regulation of the absolute number of 
LT-HSCs or the function of LT-HSCs, we performed competitive reconstitution 
assays using equal numbers of purified LT-HSCs. Five hundred CD34-Flt3-
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LSK cells, purified by cell sorting from B6 or Alox15 BM, were mixed with wild-
type congenic competitor BM cells and injected into lethally irradiated recipient 
mice. At all times post-reconstitution, there was a significant decrease in the 
percentage of Alox15-derived blood cells (Figure 24B). Analysis of BM at 12 
weeks post-reconstitution showed a decrease in the percentage and absolute 
number of Alox15-derived LSK and CD34-Flt3-LSK compared to B6 (Figure 24C). 
These data demonstrate that 12/15-LOX regulates the function of LT-HSC. 
To determine the mechanism whereby 12/15-LOX regulates LT-HSC, we 
compared the rates of cell death and proliferation in Alox15 and B6 HSC. B6 and 
Alox15 LSK exhibited comparable levels of cell death ex vivo using both TUNEL 
and AnnexinV/DAPI staining (Figure 25A-B). In addition, B6 and Alox15 LSK 
exhibited similar cell death after sorting and in vitro culture with limiting levels of 
cytokines (Figure 25C). Thus, 12/15-LOX does not regulate apoptosis of HSC. 
However, Alox15 LSK contained an increased percentage of cycling cells 
compared to wild-type (Figure 26A). This difference was most dramatic in the 
CD34-LSK subset in which there was a decrease in the percentage of Alox15 
cells in G0 (31.9% vs. 59.7%) but increased percentage of cells in G1 (38.5% vs. 
17.3%) and SG2M (24.0% vs. 11.6%) (Figure 26B). Thus, 12/15-LOX regulates 
the number, proliferation and function of primitive LT-HSCs. As LT-HSCs 
proliferate, they may differentiate rather than self-renew leading to depletion of 
the LT-HSC population. To formally test this hypothesis, we next tested whether 
12/15-LOX regulates self-renewal.   
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Defective self-renewal in Alox15 HSC 
We tested whether 12/15-LOX regulates self-renewal capacity using two 
approaches. In the first, we compared the self-renewal capacity of Alox15 and B6 
HSCs in serial transfer assays in the absence of competitors. B6 and Alox15 BM 
were transplanted into lethally irradiated mice. After 16 weeks, the bone marrow 
was isolated and transplanted into a second lethally irradiated recipient (Figure 
27A). Alox15 BM was able to reconstitute lethally irradiated primary recipient 
mice but recapitulated the defects in Alox15 mice described above, compared to 
the hematopoietic profile of primary recipients of B6 BM (Figure 14). However, 
when BM cells from primary recipients were serially transferred, there was a 
marked reduction in the survival of secondary recipients of Alox15 BM compared 
to B6 (Figure 27B). The morbidity was not due to development of MPD because 
the secondary recipients had comparable levels of neutrophils (Figure 27C). 
These data demonstrate that Alox15 HSCs have a decreased capacity to self-
renew compared to wild-type HSC. 
In the second approach we compared functionality of B6 and Alox15 HSCs 
following treatment with 5-FU (200 mg/kg, i.p.), which depletes the mature 
hematopoietic department resulting in division of HSCs. During competitive 
reconstitutions, HSCs must be able to home to a bone marrow environment that 
is altered after irradiation. The 5-FU approach has an advantage because it tests 
the ability of HSCs to self-renew in their native niches. HSC self-renewal capacity 
was assessed by determining the ratios of LSK to myeloid progenitors (MP) and 
CLPs at day 4 post-injection, when the HSC are expected to be cycling in 
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order to replenish the hematopoietic compartment. If the ratios of CLP/LSK or 
MP/LSK are increased in 5-FU treated Alox15 BM compared to 5-FU treated 
wild-type controls, it would indicate a preference for Alox15 HSCs to differentiate 
rather than to self-renew while a reduced ratio indicates a preference for Alox15 
HSCs to self-renew rather than differentiate (Figure 28). On day 4 post-5-FU 
treatment, Alox15 BM contained a greater percentage of differentiated cells 
compared to wild-type including an increase in the percentage of MP and 
increased percentage and numbers of CLPs (Figure 29A-C). Moreover, the ratios 
of MP/LSK, and CLP/LSK were increased compared to wild-type, demonstrating 
a decreased capacity for Alox15 HSC to self-renew and an asymmetric division 
skewed toward differentiation (Figure 29A). B6 and Alox15 LSK displayed similar 
resistance to 5-FU per se because at day 2 post-5-FU treatment, there were no 
differences in the numbers or percentages of LSK, MP or CLP. Furthermore, by 
day 8 post 5-FU treatment, the LSK subset in B6 had expanded while Alox15 
exhibited a marked reduction in number and percentage of LSK. (Figure 29B-C). 
The reduction in LSK in BM of 5-FU-treated Alox15 mice on day 8 may be due to 
exhaustion of the capacity of HSC to self-renew as required to maintain the 
populations of LSK and progenitors. 5-FU-treated Alox15 mice also exhibited 
decreased survival; 87.5% (7/8) of Alox15 mice succumbed to treatment 
compared to 12.5% (1/8) for B6 mice (Figure 29D). The cause of death of the 5-
FU-treated Alox15 mice appeared to be severe anemia, as the HCT at day 8 
post-treatment was 14.52% + 4.81% for Alox15 mice versus 32.53% + 8.08% for 
B6 mice. The findings of increased proliferation but decreased numbers of 
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LT-HSC in Alox15 mice, decreased survival of recipients that received serially 
transferred Alox15 bone marrow and the increased ratios of Alox15 
progenitor/LSK during 5-FU assays, when taken together, effectively 
demonstrate that 12/15-LOX regulates HSC self-renewal.  
Defective self-renewal of Alox15 HSC is associated with reduction 12/15-LOX-
dependent generation of lipid mediators and ROS  
In order to determine which products of 12/15-LOX activity mediate HSC 
function, we compared levels of ROS and lipid metabolites in B6 and Alox15 
progenitors. Purified Alox15 LSK isolated by cell sorting exhibited increased 
basal ROS levels ex vivo using the oxygen-sensitive CM-H2DCFDA probe 
compared to B6 (Figure 30A). Because ROS levels are known to be decreased 
in LT-HSC, the increase in basal ROS levels is likely a reflection of the 
decreased numbers of LT-HSC within the Alox15 LSK (Figure 24) (Jang and 
Sharkis, 2007). Interestingly, however, wild-type LSK exhibited a greater fold 
increase in ROS compared to Alox15 after loading with exogenous AA indicating 
that 12/15-LOX-mediated ROS production is in fact defective in Alox15 LSK 
(Figure 30B).  Hence, we speculate that 12/15-LOX-mediated ROS production 
may contribute to 12/15-LOX signaling in HSCs. However, in the HSC it is 
difficult to restore 12/15-LOX dependent ROS without affecting basal ROS, which 
is increased due to other oxidases such as other enzymes involved in lipid 
metabolism, NADPH-oxidases and mitochondria. In the future, it would be 
interesting to elucidate the effects of these other oxidases in Alox15 HSC that 
may contribute to the increased basal ROS levels and may also effect HSC 
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function. In Chapter 3, we will elucidate that one effect of 12/15-LOX-generated 
ROS is to regulate ICSBP/IRF-8 transcription factor nuclear accumulation 
through redox-dependent signaling. 
 We also compared the generation of 12/15-LOX-mediated lipid 
metabolites between B6 and Alox15 BM and progenitors. B6 and Alox15 BM or 
Lin- cells enriched by column purification were loaded with 10 µM AA and lipid 
products were detected using mass spectroscopy (Figure 31A). Alox15 BM 
exhibited decreased 12(S)-HETE and 15(S)-HETE production while Alox15 Lin- 
cells produced less 12(S)-HETE and 13(S)-HODE compared to B6 (Figure 31B). 
These differences were specific for 12/15-LOX products as there were no 
differences in the 5-LOX product 5(S)-HETE. Interestingly, Alox15 BM also 
exhibited decreased levels of the novel recently described 15(S)-HETE derivative 
15-oxo-ETE, reported to inhibit proliferation in HUVEC cells (Wei et al., 2009). 
We speculate that 12/15-LOX lipid product signaling by 12(S)-HETE and 13(S)-
HODE may mediate the effects of 12/15-LOX on HSC function.  
 As described in the introduction, 12/15-LOX produces multiple products 
found in both the cell membrane, in the cytoplasm and released outside the cell. 
The mass spectroscopy assay used only measures specific lipid products that 
are released into the supernatant and it is likely that other 12/15-LOX-generated 
products not measurable by our assay play a role in cell signaling that regulates 
HSC function. Moreover, products of 12/15-LOX often act in combination, which 
makes testing a single 12/15-LOX in isolation difficult to interpret. Product re-
diversion in the absence of 12/15-LOX occurs and another product of 
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different AA-metabolizing enzyme such as 5-LOX may in fact regulate HSC 
function. Lastly, lipid metabolites are very short-lived and stable derivatives of the 
12/15-LOX products may be needed to test their ability to regulate HSC function. 
 Despite these challenges, we tested the ability of 12/15-LOX products, 
12(S)-HETE and 15(S)-HETE, to alter HSC proliferation in vitro. BM cells from 
Alox15 mice were isolated and treated with 12(S)-HETE and 15(S)-HETE in 
varying concentrations for 30 minutes or overnight prior to cell cycle analysis. 
Both 12(S)-HETE and 15(S)-HETE increased the percentage of cells in G0 and 
decreased the percentage of cycling cells in the total BM population (Figure 
32A). These effects were not dose-dependent and occurred at the lowest dose of 
1 µM for both 12(S)-HETE and 15(S)-HETE. However, neither 12(S)-HETE nor 
15(S)-HETE alone had any effect on the proliferation of LSK cells (Figure 32B-
C). Therefore, 12(S)-HETE nor 15(S)-HETE in isolation regulates HSC 
proliferation, rather 12/15-LOX likely regulates HSC with greater complexity.  
Products of 12/15-LOX may also regulate mature cells differently than LSK, as 
12(S)-HETE and 15(S)-HETE both effected the proliferation of the total BM 
population but not the LSK cells. Moreover, to regulate their cell division in vivo 
HSC rely on signals provided by their niche, which is absent from this in vitro 
assay. 
12/15-LOX regulates ICSBP/IRF-8 nuclear accumulation and consequently 
canonical Wnt signaling in hematopoietic progenitors 
We previously reported that 12/15-LOX regulates ICSBP/IRF-8 nuclear 
accumulation in peritoneal macrophages and Mac1+Gr1+ splenocytes 
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(Middleton et al., 2006a; Middleton et al., 2006b). ICSBP/IRF-8 is also reduced in 
aging stem cells and its targets, including Dab2, are involved in signaling 
pathways implicated in HSC function (Hocevar et al., 2003; Stirewalt et al., 
2008). Therefore, we investigated whether 12/15-LOX regulates ICSBP/IRF-8 in 
hematopoietic progenitors. ICSBP/IRF-8 protein in nuclear extracts of B6 and 
Alox15 Lin-cKit+ cells enriched by column purification was quantified by 
immunoblot ex vivo. The levels of nuclear ICSBP/IRF-8 protein were decreased 
in Alox15 progenitors compared to B6 (Figure 33A) due to dysregulation at a 
post-translational level as levels of ICSBP/IRF-8 total protein (MPER lysates) and 
mRNA were not statistically different (Figure 33B-C).  
To determine whether the decrease in ICSBP/IRF-8 nuclear accumulation 
affected the expression of ICSBP/IRF-8 target genes in HSC, we analyzed 
mRNA levels of known ICSBP/IRF-8-regulated genes using Q-PCR in B6 and 
Alox15 LSK enriched by sorting. ICSBP/IRF-8 is known to negatively regulate 
Dab2 and positively regulate Nf-1, Blimp1 and p15INK4b (Rosenbauer et al., 
2002; Schmidt et al., 2004; Zhu et al., 2004). Consistent with this, Dab2 mRNA 
was increased while Nf-1, Blimp1 and p15INK4b mRNA were decreased in 
Alox15 compared to wild-type LSK (Figure 33D).  
We also analyzed expression of other genes that regulate HSC function not 
believed to be directly regulated by ICSBP/IRF-8 including Hes1, Bmi, Hoxb4 
and Gfi-1. Of these genes, only Hes1 was significantly decreased in Alox15 
compared to wild-type LSK (Figure 33D). Because Hes1 is also decreased when 
canonical Wnt signaling is inhibited (Fleming et al., 2008) and because the 
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ICSBP/IRF-8 target Dab2 negatively regulates canonical Wnt signaling by 
inhibiting disheveled and stabilizing axin (Hocevar et al., 2003; Jiang et al., 
2008), we investigated whether 12/15-LOX regulates canonical Wnt signaling. 
We first determined that Dab2 protein was increased in Alox15 Lin-cKit+ cells 
(Figure 34A).  Because increased Dab2 leads to degradation of downstream 
mediators of canonical Wnt signaling including β-catenin, we measured β-catenin 
levels in wild-type and Alox15 progenitors. Indeed, β-catenin protein was 
decreased in total lysates of Alox15 Lin-cKit+ progenitors compared to wild-type 
(Figure 34B). These data implicate 12/15-LOX as a novel regulator of canonical 
Wnt signaling. Canonical Wnt signaling is known to regulate HSC quiescence 
and self-renewal (Fleming et al., 2008; Luis et al., 2009; Zhao et al., 2007) and 
therefore the dysregulation of the Wnt signaling pathway including β-catenin, 
may be at least one important mechanism underlying the reduced quiescence 
and self-renewal capacity in Alox15 HSC. 
The PI3-K pathway is another signaling pathway implicated in HSC 
function. We have previously shown that phosphorylated Akt, which is 
downstream of PI3-K was increased in developing Alox15 BM and that PI3-K 
regulated nuclear accumulation of ICSBP/IRF-8 in Alox15 splenocytes(Middleton 
et al., 2006b). Moreover, mice with activated PI3-K due to deletion of PTEN 
exhibited HSC defects including loss of quiescence and developed leukemia. 
These effects were mediated downstream by mammalian target of rapamycin 
(mTOR) signaling. Treatment of these mice with the mTOR inhibitor rapamycin 
reduced proliferation of PTEN-deficient HSC (Yilmaz et al., 2006). Therefore, 
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we speculated that activated PI3-K signaling, specifically mTOR, may regulate 
the defective HSC function in Alox15 mice. We tested whether treatment with 
rapamycin reduced HSC proliferation in Alox15 mice. Treatment of Alox15 mice 
with rapamycin for seven days decreased the proliferation amongst the total 
Alox15 BM population (Figure 35A) demonstrating that the biological activity of 
rapamycin and that the enhanced proliferation in mature Alox15 cells may be due 
in part to mTOR signaling. On the other hand, Alox15 LSK displayed no 
difference in proliferation in the presence of rapamycin (Figure 35B). Therefore, 
the increased proliferation in Alox15 LSK is not due to the PI3-K-AKT-mTOR 
pathway. 
In order to directly address whether β-catenin regulates HSC function in 
Alox15 mice, we attempted to introduce a murine stem cell retrovirus (MigR) 
containing non-degradable β-catenin into Alox15 BM. However, retroviral 
transduction of Alox15 cells was challenging. Treatment of Alox15 mice with 5-
FU caused depletion of the LSK and progenitors (Figure 29). Therefore, we 
tested the feasibility of retroviral transduction of fetal liver cells, which do not 
need treatment with 5-FU. Alox15 fetal liver cells were retrovirally transduced at 
high levels initially. However, lethally irradiated recipients that received Alox15 
retrovirally tranduced cells exhibited low survival rates, while all of the recipients 
of B6 retrovirally transduced cells survived (Figure 36A). The few surviving 
recipients of Alox15-tranduced cells exhibited low levels of GFP+ Mig retrovirus 
(A) while the B6 retrovirally transduced cells were present at high numbers 
(Figure 36A). Furthermore, surviving recipients of Alox15 transduced cells 
96 
 
97 
 
98 
 
but not recipients of B6 retrovirally tranduced cells, exhibited an expansion of 
rare host cells (Figure 36B). Thus, it appears that Alox15 cells exhibit greater 
sensitivity to retroviral transduction and do not survive/expand after transfer into 
irradiated recipients. Lowering the dose of irradiation to the host or the addition of 
competitor B6.SJL cells improved survival of recipients but did not improve 
recovery of Alox15 retrovirally tranduced cells. The retroviral reconstitution in 
Alox15 HSCs needs to be further optimized in future studies to directly address 
the pathway whereby 12/15-LOX regulates HSC. 
Implications 
These studies establish the importance of unsaturated fatty acid 
metabolism in hematopoiesis by demonstrating that Alox15 mice have a cell-
autonomous defect in hematopoietic development. Depletion of 12/15-LOX 
results in a primary defect in HSC function. 12/15-LOX directly regulates the 
number, proliferation and function of LT-HSCs. Furthermore, Alox15 HSCs 
exhibit a decreased capacity to self-renew. The defects in Alox15 HSCs are 
associated with a selective decrease in 12/15-LOX-mediated ROS and lipid 
metabolites and are at least partly due to dysregulation of the transcription factor 
ICSBP/IRF-8 and its downstream targets and to disruption of canonical Wnt 
signaling.   
Because Alox15 HSCs exhibit decreased quiescence, the striking 
phenotype observed during the 5-FU assays at day 4 may be partially due to 
increased sensitivity of Alox15 LSK to 5-FU. However, the sensitivity of 5-FU at 
day 2 is similar between B6 and Alox15 LSK, suggesting that 5-FU is not 
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acting directly on Alox15 LSK. Moreover, the increased numbers of Alox15 CLP 
at day 4 compared to B6 demonstrate that Alox15 LSK are skewed in favor of 
differentiation rather than self-renewal. The increased ratio of progenitors 
compared to LSK at day 4, support the possibility that the exhaustion in the LSK 
population is at least partly due to a decrease in self-renewal. The conclusion 
that 12/15-LOX regulates self-renewal is also supported by the defect of Alox15 
BM cells during serial reconstitution assays and by depletion of the LT-HSC 
population in Alox15 BM.  
ROS, which are functional by-products of 12/15-LOX activity (Conrad, 
1999), are known to regulate HSC function. Because LT-HSCs exhibit decreased 
ROS (Jang and Sharkis, 2007), the finding that Alox15 LSK exhibit increased 
basal levels of ROS is likely a reflection of the reduction in LT-HSCs amongst 
Alox15 LSK. Furthermore, basal ROS levels in HSCs may be determined by 
other oxidases, such as NADPH-oxidase (Piccoli et al., 2007). In any case, 
increased levels of ROS may contribute to the defect in HSC function and self-
renewal (Ito et al., 2006; Miyamoto et al., 2007; Tothova et al., 2007; Jang and 
Sharkis, 2007). Moreover, ROS are known to regulate cell cycle progression 
(Iiyama et al., 2006) and hence may in fact contribute to the increased cycling in 
Alox15 LSK. However, we have demonstrated that 12/15-LOX-mediated ROS 
production is defective in Alox15 LSK and hence may contribute to 12/15-LOX 
signaling in HSCs. 
Deficiency in 12/15-LOX also resulted in a marked reduction in the 
generation of select 12/15-LOX lipid mediators by hematopoietic progenitors. 
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12(S)-HETE and 13(S)-HODE were decreased while similar levels of 15(S)-
HETE and the 5-LOX product 5(S)-HETE were produced by Alox15 compared to 
B6 progenitors. On the other hand, in Alox15 total BM cells there were decreased 
12(S)-HETE and 15(S)-HETE but similar levels of 13(S)-HODE. The differences 
in product formation between BM cells and the enriched progenitors are likely 
due to the preference of murine 12/15-LOX to synthesize 12(S)-HETE rather 
than 15(S)-HETE and differences in substrate (AA vs linoelic acid) availability.  
Lipid metabolites of 12/15-LOX may regulate HSC function intrinsically 
either individually or in combination and may act on multiple signal transduction 
pathways including activation of protein kinase C by 12(S)-HETE, and MAPK by 
13(S)-HODE (Conrad, 1999). Some 12/15-LOX products function by 
incorporation into cell membranes, which can alter phosphoinositol (Girton et al., 
1994) and receptor signaling (Takata et al., 1994). Moreover, 12/15-LOX 
products directly influence gene transcription by binding and activating 
transcription factors such as PPAR-γ (Huang et al., 1999). Recent studies have 
shown that the recently described 15(S)-HETE derivative 15-oxo-HETE inhibits 
HUVEC proliferation (Wei et al., 2009). Further studies are required to determine 
how 12/15-LOX lipid products regulate HSC proliferation and function. 
Interestingly, fatty acid metabolism mediated by other enzymes that also 
target AA as their substrate have been implicated in normal and leukemic HSC 
function. The cyclooxygenase product prostaglandin E2 is known to signal 
extrinsically through its receptor on HSC to promote self-renewal by enhancing 
canonical Wnt signaling and β-catenin accumulation (North et al., 2007) 
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(Goessling et al., 2009). Prostaglandin E2 has also been shown to regulate HSC 
progression into cell cycle (Hoggatt et al., 2009). In addition, it was recently 
reported that 5-lipoxygenase-deficient mice are protected from BCR-ABL-
induced CML through inhibition of leukemic stem cell differentiation. In this study, 
we demonstrate a seemingly opposing role for 12/15-LOX since 12/15-LOX 
promotes self-renewal of normal HSC and suppresses development of myeloid 
leukemia (Middleton et al., 2006b). Because cyclooxygenase, 5-LOX and 12/15-
LOX share AA as a substrate, it will be interesting in the future to investigate 
whether substrate availability or substrate rediversion may contribute to the 
phenotypes observed in the HSC compartment in the absence of 12/15-LOX or 
5-LOX.   
We have demonstrated that 12/15-LOX regulates nuclear ICSBP 
accumulation in HSC. Intriguingly, ICSBP/IRF-8 has been proposed to play a role 
in HSC function as aging wild-type murine and human HSC have decreased 
levels of ICSBP/IRF-8 (Stirewalt et al., 2008). PU.1, a transcription factor that 
interacts with ICSBP/IRF-8 is required for the capacity of HSC to self-renew 
(Iwasaki et al., 2005). Both ICSBP/IRF-8 and PU.1 bind to the Dab2 promoter 
and ICSBP/IRF-8 inhibits Dab2 expression (Rosenbauer et al., 2002) (Figure 37). 
Dab2 functions as a negative regulator of canonical Wnt signaling by inhibiting 
dishevelled-3 and by stabilizing axin leading to degradation of mediators of 
canonical Wnt signaling including β-catenin (Hocevar et al., 2003; Jiang et al., 
2008; Figure 34; Figure 37). Axin over-expression has been shown to negatively 
regulate HSC self-renewal (Reya et al., 2003). Other mediators of canonical 
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Wnt signaling including β-catenin have also been shown to regulate self-renewal, 
quiescence and function of HSCs (Nemeth et al., 2006; Zhao et al., 2007; 
Fleming et al., 2008; Luis et al., 2009). Consistent with these data, Dab2 gene 
and protein expression were amplified in Alox15 HSCs (Figure 37). Dab2 
promotes β-catenin degradation leading to a decrease of β-catenin in Alox15 
progenitors (Figure 37). The data presented indicate that 12/15-LOX may act 
upstream of ICSBP/IRF-8 to promote Wnt signaling and hence self-renewal by 
inhibiting transcription of Dab2. Therefore, 12/15-LOX is a novel regulator of 
canonical Wnt signaling. 
HSC function and hematopoietic differentiation are related and disruptions 
in HSC function can lead to the development of leukemia; for example, in the 
floxed PTEN mouse (Yilmaz et al., 2006). Alox15 mice develop a chronic 
myelogenous leukemia-like MPD in 15% of the mice over the course of a year. It 
is possible that the disruption in HSC function contributes to the development of 
MPD in Alox15 mice (Middleton et al., 2006b). Dysregulation of ICSBP/IRF-8 and 
decreased 12/15-LOX activity, particularly levels of 12(S)-HETE, are also 
associated with human CML (Stenke et al., 1991; Takayama et al., 1983). The 
contribution of decreased lipid mediators to the leukemic state remains largely 
unknown, although eicosanoid products may induce apoptosis of myeloid 
leukemic cell lines (Li et al., 2005; Mahipal et al., 2007). Because of the 
development of a myeloid leukemia in Alox15 mice, we hypothesized that 12/15-
LOX also regulates myelopoiesis which we will address in Chapter 3. 
 In summary, we have found that 12/15-LOX-mediated fatty acid 
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metabolism regulates the asymmetric division of HSCs by promoting quiescence 
and self-renewal of LT-HSC. In the absence of 12/15-LOX, HSCs exhibit 
increased proliferation and a bias in their asymmetric division toward 
differentiation rather than self-renewal. Furthermore, we show that depletion of 
12/15-LOX products is associated with a defect in nuclear accumulation of 
ICSBP/IRF-8 and subsequent canonical Wnt signaling. Furthermore, I define 
12/15-LOX as a novel regulator of canonical Wnt signaling. The data in this 
chapter demonstrate that signaling downstream of fatty acid metabolism is an 
important mechanism whereby HSC function is mediated. Further understanding 
of these mechanisms may have implications for hematopoiesis, leukemia and 
hematopoietic aging. 
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CHAPTER 3: IRF-8-driven monopoiesis is dependent upon 12/15-
lipoxygenase mediated redox signaling 
 Myelopoiesis is the process whereby myeloid cells, granulocytes and 
monocytes, are generated from HSCs. Hematopoietic differentiation from HSC 
gives rise to cells that are progressively more restricted in their potential fate as 
they commit to various lineages.  For example, HSCs differentiate into MPP that 
propagate both myeloid and lymphoid cells (Wilson et al., 2007). Further 
differentiation of MPPs leads to the generation of CMP that can only sustain 
erythropoiesis by differentiating into MEP and myelopoiesis by differentiating into 
GMP, which in turn differentiate into either granulocytes or monocytes (Akashi et 
al., 2000). Although phenotypic profiles can be used to distinguish hematopoietic 
progenitors at various stages of differentiation, hematopoiesis occurs along a 
continuum so that phenotypically defined progenitor populations can exhibit 
heterogeneity with regard to their ability to commit and differentiate to alternative 
lineages.  
 During myelopoiesis, IRF-8 functions in conjunction with PU.1 to activate 
gene transcription that promotes monocytic differentiation while inhibiting gene 
transcription that promotes granulocytic differentiation (Tamura et al., 2000). 
Loss of IRF-8 transcriptional activity results in defects in monocytic development 
and enhanced granulocytic differentiation (Scheller et al., 1999; Tsujimura et al., 
2002). Transcriptional activity of IRF-8 is dependent on its translocation to the 
nucleus from the cytoplasm and our lab previously showed that IRF-8 nuclear 
accumulation requires 12/15-lipoxygenase (12/15-LOX)-mediated signaling 
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(Middleton et al., 2006a; Middleton et al., 2006b). However, the mechanism 
whereby 12/15-LOX promotes nuclear accumulation of IRF-8 has not been 
elucidated. In this chapter, I present evidence which demonstrates that 12/15-
LOX regulates ICSBP/IRF-8 by redox signaling and implicates SHP-2 as a redox 
sensitive factor. 
  Although much is known about the transcription factors that regulate 
myeloid cell specification, less is understood about the upstream signaling 
pathways required for these cell fate decisions. In this chapter, I present data 
which demonstrate that myelopoiesis is regulated by a novel 12/15-LOX-
dependent signaling pathway.  Little was previously known of the consequences 
of 12/15-LOX signaling during myelopoiesis. Although others reported that 
addition of 12(S)-HETE and 15(S)-HETE to human CD34+ progenitors decreased 
the numbers of granulocyte-macrophage colonies in methylcellulose assays 
(Desplat et al., 2000), the role of 12/15-LOX in regulation of granulocytic and 
monocytic lineage specification remained to be determined. 
 ROS generated as byproducts of 12/15-LOX-mediated lipid metabolism 
also function as second messengers by regulating cellular redox signaling. For 
instance, ROS generated by lipoxygenases can oxidatively modify proteins such 
as SHP-2 resulting in their inactivation (Pani et al., 2000; Chen et al., 2009a). 
Interestingly, SHP-2 negatively regulates ICSBP/IRF-8 transcriptional activity, 
known to promote monocyte differentiation (Huang et al., 2006; Tsujimura et al., 
2002) and inhibition of SHP-2 results in decreased granulocyte differentiation 
(Jack et al., 2009). However, a role for ROS per se has not been previously 
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demonstrated in GMP or in the regulation of cell fate decisions.  
 Because monocyte numbers are reduced (Chapter 1) while the 
percentage of granulocytes is increased in Alox15 mice (Middleton et al., 2006b), 
I hypothesized that 12/15-LOX regulates myeloid cell fate decisions. In this 
chapter, I present data that establish that Alox15 myeloid cell development is 
skewed towards the granulocytic lineage at the expense of monopoiesis. 
Furthermore, the data indicate that the bias in cell fate is due to 12/15-LOX-
dependent redox signaling that mediates nuclear accumulation of IRF-8 to drive 
monopoiesis and inhibit granulopoiesis. 
Alox15 progenitors exhibit enhanced granulopoiesis and decreased monopoiesis  
 We previously demonstrated that 12/15-LOX-deficient Alox15 mice had 
reduced numbers of monocytes in the blood and increased percentage of 
granulocytes in the blood, spleen and bone marrow (BM) (Kinder et al submitted; 
(Middleton et al., 2006b). Therefore, we hypothesized that 12/15-LOX regulates 
myelopoiesis. Using real time PCR analysis of enriched progenitor subsets, we 
determined that 12/15-LOX was expressed at varying levels throughout 
myelopoiesis (Figure 38) with the highest levels of 12/15-LOX expression in CMP 
and MEP. Because these progenitors have erythroid potential, these data were 
consistent with the fact that 12/15-LOX products were involved in erythroid 
differentiation (Chapter 1; Kuhn and Brash, 1990; van Leyen et al., 1998). 
However, 12/15-LOX was also expressed in HSC and GMP at levels similar to 
Gr1+ splenocytes. 
 To test the hypothesis that 12/15-LOX regulates myelopoiesis, we 
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plated cells from B6 and Alox15 mice in methylcellulose containing IL-6, IL-3, 
stem cell factor (SCF) and erythropoietin (Epo) and compared the frequency of 
colony-forming units-granulocyte (CFU-G) to that of colony-forming units-
macrophage (CFU-M). BM cells from Alox15 mice generated an increased ratio 
of CFU-G to CFU-M compared to BM cells from B6 mice (Figure 39A). BM cells 
from Alox15 mice gave rise to an increased number of total colonies, due to an 
increased number of CFU-G and CFU-granulocyte-macrophage (CFU-GM). In 
contrast, Alox15 BM cells gave rise to a decreased number of CFU-M compared 
to B6 (Figure 39A). Splenocytes from Alox15 mice had a trend towards increased 
total number of colonies and also generated an increased ratio of CFU-G to 
CFU-M. Like BM, splenocytes gave rise to an increased number of CFU-G and 
CFU-GM (Figure 39B). These data demonstrate that 12/15-LOX indeed regulates 
myelopoiesis and that absence of 12/15-LOX results in skewing of myelopoiesis 
towards granulocytic development. 
 Similar to BM cells plated in methylcellulose in the presence of IL-3, IL-6, 
Epo and SCF (Figure 40A), BM cells from Alox15 mice grown in the presence of 
GM-CSF also were skewed towards granulocyte development as indicated by an 
increased CFU-G/CFU-M ratio compared to B6 (Figure 40A). The skewing 
towards granulocyte development in the presence of GM-CSF was a result of 
increased numbers of Alox15 CFU-G colonies and hence enhanced 
granulopoiesis compared to B6. Similarly, the numbers of CFU-GM were also 
increased in Alox15 compared to B6 in the presence of GM-CSF (Figure 40A). 
These data provide additional evidence for enhanced granulopoiesis by 
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Alox15 cells.  
 The cytokines provided in the experiments described above, IL-3, IL-6, 
SCF and Epo or GM-CSF, do not instruct lineage fate but rather support 
development of multiple myeloid cell fates. In order to determine the effect of 
instructive cytokines on the differentiation of B6 and Alox15 BM cells, we plated 
B6 and Alox15 BM cells in methylcellulose in the presence of M-CSF or G-CSF 
and quantified colony number and phenotype. Interestingly, cells from Alox15 BM 
gave rise to an increased number of total colonies in the presence of both M-CSF 
and G-CSF compared to cells from B6 BM. However, in the presence of M-CSF, 
cells from Alox15 BM generated more CFU-GM, but not CFU-M. In contrast, in 
the presence of G-CSF, cells from Alox15 BM gave rise to an increased number 
of both CFU-GM and CFU-G compared to cells from B6 BM (Figure 40B). Taken 
together, these data demonstrate that Alox15 BM cells exhibit an increased 
frequency of CFU-GM and enhanced granulocytic differentiation. 
 The increased number of total myeloid colonies that developed in 
methylcellulose assays with Alox15 cells suggested that there might be an 
increased number of myeloid progenitors in Alox15 BM compared to B6. 
Specifically, the increase in CFU-GM in the presence of all cytokines including M-
CSF, suggest that the GMP population is specifically increased in Alox15 mice. 
Accumulation of defective GMP in Alox15 mice 
 To determine whether 12/15-LOX regulates the numbers of myeloid 
progenitor populations such as GMP in unmanipulated mice, we employed 
multicolor flow cytometric analysis to determine the percentage and numbers 
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of phenotypic progenitor populations. At all ages tested, Alox15 mice had similar 
percentages of Lin-Sca1+cKit+ cells (LSK, a population enriched for murine HSC), 
CMP and MEP but an increased percentage of GMP in the BM compared to B6 
(Figure 41A-C). Using manual counts of total bone marrow cells coupled with the 
percentages of the progenitor populations determined by multicolor flow 
cytometric analysis, we determined that absolute numbers of GMP were also 
increased in Alox15 BM compared to B6 (Figure 41E). The increased percentage 
of GMP was also evident in Alox15 spleen (Figure 41D).  
 There are several potential explanations for the increased number of GMP 
progenitors in Alox15 mice. First, CMP may produce more GMP at the expense 
of MEP. Although possible, this is not likely as there were similar numbers of 
erythroid progenitors (BFU) produced from Alox15 BM in methylcellulose assays 
(Figure 39A), and similar numbers of MEP in B6 and Alox15 mice (Figure 41). 
Second, Alox15 GMP may expand by proliferating and/or through enhanced 
survival. Alternatively, Alox15 GMP differentiation may be blocked resulting in 
accumulation of GMP as they fail to progress from this differentiative stage.  
 To determine whether Alox15 GMP exhibit enhanced proliferation, we 
performed cell cycle analysis of B6 and Alox15 GMP ex vivo using incorporation 
of Hoechst dye, which determines DNA content. B6 and Alox15 GMP had 
comparable percentages of cells in SG2M (Figure 42A). Moreover, cell survival 
was similar between B6 and Alox15 GMP as measured by the percentage of 
cells expressing AnnexinV, an apoptotic marker, ex vivo and after stimulation 
with SCF in vitro (Figure 42B-C). Therefore, Alox15 GMP do not appear to 
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be increased due to enhanced proliferation or decreased apoptosis. 
 To test the hypothesis that GMP accumulate in Alox15 mice due to a block 
in differentiation, we isolated enriched populations of LSK, CMP and GMP from 
BM of B6 and Alox15 mice by cell sorting and compared their capacity to 
differentiate in methylcellulose assays. LSK and CMP from Alox15 mice both 
generated increased numbers of CFU-G but decreased numbers of CFU-M 
compared to B6 resulting in increased ratios of CFU-G/CFU-M compared to B6 
(Figure 43A-B). These data recapitulated results of the methylcellulose assays 
using whole BM cells. 
 On the other hand, GMP from Alox15 mice exhibited a defect in the 
capacity to differentiate in methylcellulose assays. GMP from Alox15 mice 
generated fewer total colonies, gave rise to significantly fewer M-CFU, and 
exhibited subtle decreases in CFU-G and CFU-GM. In spite of the subtle 
decrease in CFU-G, the ratio of CFU-G/CFU-M from Alox15 GMP was increased 
compared to B6 as we observed for LSK and CMP  (Figure 43C). Although these 
data were consistent with a skewing towards granulocytic differentiation and 
defective monocytic development, it was not clear whether the defect in Alox15 
GMP was specific for monocytic development. To determine the specificity of 
defective differentiation of Alox15 GMP, we compared differentiation of B6 and 
Alox15 GMP in the presence of the instructive cytokines M-CSF or G-CSF in 
methylcellulose assays. GMP from B6 and Alox15 mice produced similar 
numbers of granulocytic colonies in response to G-CSF demonstrating that 
Alox15 GMP did not exhibit defective differentiation nor cytokine 
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hypersensitivity to G-CSF per se.  However, GMP from Alox15 mice gave rise to 
fewer monocytic colonies in response to M-CSF than GMP from B6 mice (Figure 
43D). 
 These data illustrate that there is an accumulation of GMP in Alox15 mice 
likely caused by a selective block in monocytic differentiation and decreased exit 
from this progenitor stage. In the absence of 12/15-LOX, there is enhanced 
granulocytic development at the expense of monopoiesis. Therefore, I conclude 
that 12/15-LOX functions to promote monocytic development and inhibit 
granulocytic development. (Figure 44). 
Redox regulation of IRF-8 nuclear accumulation 
 We previously demonstrated that 12/15-LOX regulated IRF-8/ICSBP 
nuclear accumulation in mature myeloid cells (Middleton et al., 2006a; Middleton 
et al., 2006b) and in Lin-cKit+ immature myeloid progenitors (Chapter 2) (Kinder 
et al submitted). Moreover, IRF-8/ICSBP is known to critically promote monocyte 
differentiation and inhibit granulocyte development (Tamura et al., 2000; 
Tsujimura et al., 2002; Scheller et al., 1999). Therefore, we hypothesized that 
defective IRF-8/ICSBP transcriptional activity may cause the skewed 
granulopoieis and defective monopoiesis in Alox15 mice. To test this hypothesis, 
we analyzed IRF-8-regulated genes, NF-1 (Zhu et al., 2004) and Egr-1 (Tamura 
et al., 2000), in CMP and GMP from B6 and Alox15 mice. CMP and GMP from 
Alox15 mice expressed decreased levels of NF-1 and Egr-1 compared to B6 
(Figure 45A) while the mRNA levels of genes important in myeloid differentiation 
but not regulated by IRF-8, such as PU.1 and c/EPBα (Tamura et al., 2000), 
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were comparable between B6 and Alox15 progenitor subsets (Figure 45A), 
indicating a selective defect in IRF-8-mediated gene transcription. The defect in 
IRF-8/ICSBP-mediated gene transcription was not due to decreased expression 
of IRF-8/ICSBP as levels of IRF-8/ICSBP mRNA were similar between B6 and 
Alox15 CMP and GMP (Figure 45A). These data are consistent with evidence 
that 12/15-LOX can regulate IRF-8/ICSCP in a post-transcriptional manner 
(Chapter 2) (Middleton et al., 2006b).   
 To determine how 12/15-LOX regulates IRF-8 transcriptional activity in 
developing monocytes, we used B6 and Alox15 BMM, which recapitulated the 
defect in NF-1 gene expression and expressed similar levels of IRF-8 in Alox15 
CMP and GMP (Figure 45B). To determine which 12/15-LOX-products might 
regulate IRF-8-mediated gene transcription, we compared levels of lipid 
metabolites and ROS in B6 and Alox15 BMM. As expected, we found that Alox15 
BMM were defective in production of the 12/15-LOX-generated lipid metabolite 
12(S)-HETE and in basal levels of ROS compared to B6 (Figure 45C-D). 
Moreover, Alox15 BMM produced increased levels of the 5-LOX product 5(S)-
HETE in response to AA suggesting substrate re-diversion into the 5-LOX 
pathway (Figure 45C). 
  To determine the potential impact of the reduction in ROS on IRF-8 
mediated gene transcription, we treated B6 BMM overnight with a ROS 
scavenger, Tiron, which decreased levels of ROS (Figure 46A) and measured 
transcription of the IRF-8 target gene NF-1. Conversely, we treated Alox15 BMM 
with BSO, which increases ROS (Figure 46A) by inhibiting synthesis of the 
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 cellular anti-oxidant gluthathione. Interestingly, we found that NF-1 gene 
expression was regulated in part by ROS levels. The ROS scavenger Tiron 
decreased NF-1 expression in B6 BMM while the ROS inducer, BSO, restored 
NF-1 transcription in Alox15 BMM (Figure 46B). To determine whether ROS-
signaling alters NF-1 transcription by regulating the nuclear accumulation of IRF-
8, levels of IRF-8 were quantified in nuclear lysates of B6 BMM treated with Tiron 
overnight. Both B6 BMM treated with Tiron and Alox15 BMM exhibited a 
decrease in IRF-8 nuclear accumulation compared to untreated B6 BMM, 
indicating that low ROS levels contribute to the decreased nuclear accumulation 
of IRF-8 (Figure 46C). Conversely, elevation of ROS levels in Alox15 BMM by 
the addition of BSO increased IRF-8 nuclear accumulation (Figure 46D). This 
regulation was not due to alterations in IRF-8 gene expression, which was similar 
between treated and untreated B6 and Alox15 BMM (Figure 46E). Moreover, the 
nuclear levels of ICSBP/IRF-8 with the addition of BSO in Alox15 BMM were 
restored to the levels observed in untreated B6 BMM, suggesting that redox 
signaling is the primary mediator of 12/15-LOX-dependent activation of IRF-8 
(Figure 46F). These data indicate that 12/15-LOX regulates IRF-8 nuclear 
accumulation and subsequent gene transcription through ROS-mediated 
signaling. 
Redox regulation of monocyte development in Alox15 progenitors 
 If 12/15-LOX regulates nuclear IRF-8 accumulation through ROS-
mediated signaling and as IRF-8 promotes monocyte development, we expected 
that increasing ROS-signaling should also restore monocytic differentiation in 
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 Alox15 progenitors. To determine the impact of redox signaling on Alox15 
myeloid development, we plated BM cells from Alox15 mice in methylcellulose in 
the presence or absence of BSO. Interestingly, the presence of BSO increased 
Alox15 monocytic development (CFU-M) and decreased granulocyte 
development (CFU-G) in methylcellulose resulting in a decreased ratio of CFU-
G/CFU-M (Figure 47A). Increasing ROS levels through the addition of BSO also 
increased monocyte development from Alox15 GMP in methylcellulose assays. 
GMP from Alox15 mice plated in the presence of BSO generated more CFU-M 
colonies than in the absence of BSO.  This resulted in a decreased ratio of CFU-
G/CFU-M in the presence of BSO (Figure 47B). Moreover, addition of BSO to B6 
BM cells in methylcellulose had a slight trend towards increased CFU-M, though 
this was not significant (Figure 48A). The levels of ROS in B6 may be optimal for 
monocyte development and further increase of redox signaling may have a 
negative effect on cell survival (Jones, 2008). Taken together, these data indicate 
that 12/15-LOX regulates monocyte development through redox signaling and 
restoration of redox signaling in Alox15 progenitors is sufficient to restore 
monocyte development. 
 On the other hand, we also tested the effects of 12/15-LOX lipid products 
on B6 and Alox15 myeloid cell development during methylcellulose assays. 
12/15-LOX products had no effect on B6 differentiation. While 12(S)-HETE and 
13(S)-HODE had no effect on Alox15 myeloid cell development, addition of 
15(S)-HETE to methylcellulose decreased the ratio of CFU-G/CFU-M ratio by 
Alox15 progenitors (Figure 48B). Others showed that 15(S)-HETE, but not 
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13(S)-HODE, can modulate redox signaling downstream to mediate some of its 
effects (Mahipal et al., 2007). Therefore, it is possible that 15(S)-HETE regulates 
myeloid differentiation in Alox15 progenitors through redox signaling. It would be 
an interesting future direction to discern the exact contribution of 15(S)-HETE 
signaling to Alox15 myeloid cell differentiation. However, since 15(S)-HETE 
levels were similar between B6 and Alox15 BMM and Lin- progenitors (Figures 
45, 31), I concentrated on the role of 12/15-LOX-dependent ROS signaling which 
was decreased both in Alox15 BMM and LSK. Moreover, 12(S)-HETE, which is 
decreased in both Alox15 BMM and Lin- progenitors, had no effect on Alox15 
myeloid cell differentiation (Figure 48B). 
 The data presented thus far demonstrate that ICSBP/IRF-8 is 
transcriptionally active at relatively high levels of ROS. Therefore at higher levels 
of ROS a redox modification of cysteine residue(s) in ICSBP/IRF-8 or an 
upstream signal transducer promotes ICSBP/IRF-8 nuclear accumulation. 
ICSBP/IRF-8 does contain cysteines in its protein sequence. However, it is likely 
that modifications of these cysteine residues would inactivate rather than activate 
its transcriptional activity similar to the action of phosphorylation on ICSBP/IRF-8 
transcription of NF-1 (Huang et al., 2006). Moreover, most non-zinc finger 
transcription factors such as HIF1α and NF-κB are regulated by redox signaling 
by an upstream signal transducer that is the target for redox modifications 
(Haddad, 2002a).  Although I cannot formally exclude that ICSBP/IRF-8 was 
directly regulated by oxidative modifications, I hypothesized that an upstream 
regulator of ICSBP/IRF-8 was the target for redox modifications. Indeed, 
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SHP-1 and SHP-2, which negatively regulate ICSBP/IRF-8 transcriptional activity 
(Huang et al., 2006; Kautz et al., 2001), are known targets of redox modifications 
(Chen et al., 2009a; Heneberg and Draber, 2005; Weibrecht et al., 2007). 
Therefore, I hypothesized that ROS produced by 12/15-LOX may oxidize SHP-
1/2 leading to its functional inactivation. SHP-1/2 activity may be increased at low 
levels of ROS, such as in Alox15 progenitors and BMM. Moreover, I 
hypothesized that the higher activity of SHP-1/2 in Alox15 cells may inhibit 
ICSBP/IRF-8 transcriptional activity leading to a block in monocyte development 
and enhanced granulocyte development. 
 To test this hypothesis, we analyzed the effect a SHP1/2 inhibitor, NSC-
87877 would have on differentiation of Alox15 BM cells in methylcellulose 
assays. Increasing concentrations of 10 µM and 50 µM NSC-87877 restored 
monocyte development and decreased granulocyte development in 
methylcellulose assays with Alox15 BM cells. Inhibition of SHP1/2 with 50 µM 
NSC-87877 resulted in an increase in CFU-M and an accompanying decrease in 
CFU-G (Figure 49A). However, this concentration of NSC-87877 (50 µM) was 
recently shown to effect differentiation of wild-type BM cells in methylcellulose 
assays (Jack et al., 2009). Importantly, we demonstrate that 10 µM of NSC-
87877 had no effect on B6 myeloid differentiation, but still decreased the ratio of 
CFU-G/CFU-M generated by Alox15 BM cells (Figure 49B). Therefore, 
dysregulation of SHP1/2 activity may contribute to the skewed granulocyte 
differentiation of Alox15 progenitors. 
 Ideally, we would like to compare the activation of SHP-2 in B6 and 
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 Alox15 progenitors. Although I have attempted to measure phosphorylated 
stimulation concentration, progenitor cells and kinetics. Moreover, although SHP-
2 in BMM, my conditions were not optimal. I need to further optimize cytokine 
phosphorylation can increase the activity of SHP-2, it is not required (Lu et al., 
2001) and therefore may not be the best measure of its activity. A future direction 
of these studies would be to measure oxidized SHP-2 in Alox15 progenitors. 
These studies will also require further optimization, as there is no specific 
antibody for oxidized SHP-2 and introduction of oxygen to the protein lysates 
would eliminate differences.  
12/15-LOX regulates IL-12p40 expression in a redox-dependent  mechanism 
 The data presented thus far indicate that 12/15-LOX regulates ICSBP/IRF-
8 nuclear accumulation through redox signaling in Alox15 progenitors and 
immature BMM. I hypothesized that this novel pathway may be a common 
mechanism by which 12/15-LOX regulates ICSBP/IRF-8-dependent gene 
expression. Our lab previously showed that 12/15-LOX regulates IL-12p40 
expression through ICSBP/IRF-8 in mature macrophages (Middleton et al., 
2006a). Therefore, we tested whether 12/15-LOX also regulates ICSBP/IRF-8 
transcriptional activity of IL-12p40 expression in mature macrophages through 
redox signaling.  We measured levels of IL-12p40 mRNA by real time PCR 
analysis in thioglycollate-elicited macrophages from Alox15 mice in the presence 
or absence of 10 µM BSO following stimulation with 1 µg/ml LPS and 500 U/ml 
IFNγ for 4 hours. Addition of BSO restored IL-12p40 expression in Alox15 
macrophages (Figure 50A) suggesting that 12/15-LOX regulates IL-12p40 
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 expression in Alox15 macrophages through redox signaling. These results are 
consistent with the results in Dr. Middleton’s dissertation, in which she treated B6 
thioglycollate-elicited macrophages with the ROS scavenger, Tiron, and found 
decreased levels of ICSBP/IRF-8 nuclear accumulation and IL-12p40 expression. 
We also tested whether SHP-1/2 regulates IL-12p40 expression in Alox15 
macrophages. Addition of 100 µM NSC-87877 to Alox15 thioglycollate-elicited 
macrophages also increased levels of IL-12p40 expression (Figure 50B). 
Therefore, the mechanism by which 12/15-LOX regulates ICSBP/IRF-8 
transcriptional activity in immature progenitors is conserved in the regulation of 
IL-12p40 expression by mature macrophages. 
 Taken together, these data demonstrate that 12/15-LOX generated ROS 
likely inhibits SHP1/2 activity. Inhibition of SHP1/2 appears to promote nuclear 
accumulation of ICSBP/IRF-8 and thus modulates its transcriptional activity 
resulting in monocyte development and inhibition of granulocyte development in 
hematopoietic progenitors and IL-12p40 gene expression in macrophages 
(Figure 51). In the absence of 12/15-LOX, ROS levels are decreased resulting in 
increased SHP1/2 activity. As others reported, increased SHP1/2 activity leads to 
de-phosphorylation of ICSBP/IRF-8 that inhibits its association with other 
transcription factors such as PU.1 (Kautz et al., 2001) (Huang et al., 2006). This 
dysregulation of ICSBP/IRF-8 results in decreased ICSBP/IRF-8 transcriptional 
activity leading to enhanced granulocyte differentiation and decreased monocyte 
differentiation by Alox15 myeloid progenitors and decreased IL-12p40 expression 
in mature Alox15 macrophages (Figure 51). 
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Implications 
 In this chapter, I present data that 12/15-LOX promotes monocyte 
development through redox regulation of the transcription factor ICSBP/IRF-8. 
Alox15 progenitors exhibit enhanced granulopoiesis at the expense of 
monopoiesis. The excess accumulation of functional (CFU-GM) and phenotypic 
GMP in Alox15 mice is accompanied by defective monocyte differentiation, which 
is likely a result of decreased IRF-8-mediated gene transcription. We showed 
that 12/15-LOX regulates IRF-8 nuclear accumulation downstream of redox 
signaling possibly through oxidation of SHP-2. ICSBP/IRF-8 nuclear 
accumulation and transcriptional activity subsequently promotes monocyte 
differentiation and inhibits granulocyte differentiation in myeloid progenitors and 
promotes IL-12p40 expression in mature macrophages (Figure 51).  
 Because NSC-87877 recognizes both SHP-1 and SHP-2, we cannot 
discern from these experiments which mediator(s) regulate Alox15 myeloid 
differentiation. The contribution of SHP-1 versus SHP-2 is also currently not 
known in the case of normal differentiation of wild-type cells (Jack et al., 2009).  
Although the role of constitutively active SHP-2 mutations has been well 
documented in leukemia (Loh et al., 2004; Niihori et al., 2005; Schubbert et al., 
2005), the role of SHP-1 during leukemia and myeloid differentiation is less well 
understood (Bruecher-Encke et al., 2001; Luo et al., 2004). However, both SHP-
1 and SHP-2 are regulated by redox modifications of their catalytic cysteine 
residues (Chen et al., 2009a; Heneberg and Draber, 2005; Weibrecht et al., 
2007) and both can bind to ICSBP/IRF-8 (Huang et al., 2006; Kautz et al., 
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2001). A future direction would be to determine the impact on SHP-1 and SHP-2 
on myeloid cell differentiation in B6 and Alox15 mice in order to further elucidate 
the pathway by which 12/15-LOX regulates ICSBP/IRF-8 through redox 
signaling. In addition, an ICSBP/IRF-8 reporter assay could further elucidate the 
effect of redox signaling on ICSBP/IRF-8 transcriptional activity. 
 The increased numbers of GMP in Alox15 mice is likely due to an 
accumulation as a result of defective differentiation. The accumulation of GMP 
could reflect enhanced proliferation or survival, increased differentiation of CMP 
to GMP, increased self-renewal or decreased ability of GMP to progress from this 
differentiative stage. These possibilities are not mutually exclusive. For instance, 
gfi-1 regulated the numbers of GMP progenitors through a Hox9A-dependent 
mechanism that was distinct from the mechanism whereby it regulated terminal 
granulocyte formation (Horman et al., 2009). In our study, we demonstrated that 
GMP from B6 and Alox15 mice had similar rates of proliferation and survival 
(Figure 42) eliminating the first possibility. B6 and Alox15 mice had similar 
numbers of MEP (Figure 41) and similar numbers of BFU in methylcellulose 
assays in which BM and LSK were plated (Figures 38, 41). Therefore, it is 
unlikely that Alox15 CMP are differentiating to GMP at the expense of MEP. The 
decreased BFU from spleen and CMP may be a result of the defective red blood 
cell development rather than a decrease in the numbers of MEP as 12/15-LOX is 
known to regulate red blood cell development (Kuhn and Brash, 1990; van Leyen 
et al., 1998). Moreover, the absence of 12/15-LOX results in the inability of cells 
to self-renew (Chapter 2) so it is unlikely that GMP from Alox15 mice were 
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expanded due to self-renewal. Taken together, our results suggest that the 
accumulation of GMP is largely due to a block in progression from this progenitor 
stage as demonstrated by the defective differentiation of Alox15 GMP in 
methylcellulose assays (Figure 43).  However, we cannot formally exclude the 
possibility that 12/15-LOX also regulates the size of progenitor populations and 
monocyte differentiation through other distinct mechanisms. 
 BM cells, splenocytes, LSK and CMP from Alox15 mice gave rise to 
increased numbers of granulocytes compared to B6. On the other hand, GMP 
from Alox15 mice did not exhibit enhanced granulocyte differentiation during 
methylcellulose assays. These data suggest that GMP in the methylcellulose 
assays are relatively limited in their ability to differentiate to the granulocyte 
lineage in the presence of IL-3, IL-6 and SCF and a proportion may already be 
committed to the monocyte lineage. Indeed, GMP represent a stage along the 
continuum of myeloid cell differentiation and are a heterogonous population. A 
proportion of Alox15 GMP may already be committed to become monocytes. 
However, the defect in monocyte differentiation of Alox15 GMP may result in cell 
death rather than differentiation to the alternative granulocyte cell fate. Addition 
of BSO rescues the survival and differentiation of Alox15 GMP committed to the 
monocyte lineage. On the other hand, BM and spleen contain LSK and CMP, 
which are more immature and may exhibit a greater capacity to differentiate to 
the granulocytic lineage resulting in an increased number of Alox15 CFU-G in the 
methylcellulose assays. Increasing ROS levels by the addition of BSO decreased 
the number of CFU-G in methylcellulose assays with whole BM. In the 
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absence of 12/15-LOX, there may be rediversion of monocyte lineage into the 
granulocyte lineage. Indeed, signaling that promotes monocyte development 
represses granulocyte development including by transcriptional activity of IRF-8 
(Friedman, 2007; Tsujimura et al., 2002; Scheller et al., 1999; Tamura et al., 
2000). Moreover, when instructed to differentiate to granulocytes by G-CSF, B6 
and Alox15 GMP have similar numbers of granulocytic colonies. Therefore, 
Alox15 GMP are not hypersensitive to G-CSF and skewing of myelopoiesis 
towards granulocyte differentiation in the presence of non-instructive cytokines 
occurs as a result of defective monocyte differentiation.   
 The establishment of a redox-dependent mechanism for ICSBP/IRF-8 
nuclear accumulation suggests the possibility that other mediators of redox 
signaling may also regulate monocyte development. Though it was known that 
increased levels of ROS promote monocyte to macrophage transition 
(Yamamoto et al., 2009), our studies implicate an additional role for ROS-
signaling at an earlier stage of monocytic differentiation. Our finding that 
increasing ROS levels by the addition of BSO in Alox15 BM decreased 
granulocyte development are in agreement with a previous study that 
demonstrated ROS signaling, generated by dominant negative NF-κB, inhibited 
granulocyte differentiation (Nakata et al., 2004). However, the previous study did 
not examine the effects on mature monocyte development and the ROS 
generated in the previous study were at levels that mediated apoptosis. Rather, 
our studies were done at more physiological levels of ROS that did not cause 
apoptosis. ROS-signaling at physiological levels is known to promote 
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cytokine receptor signal transduction, including downstream of the cytokines Epo 
and GM-CSF (Iiyama et al., 2006; Sattler et al., 1999). It is likely that increasing 
ROS levels in Alox15 progenitors functions similarly to potentiate signal 
transduction resulting in ICSBP/IRF-8 nuclear accumulation and transcriptional 
activity and subsequent monocyte differentiation.   
 The increased levels of 5(S)-HETE in Alox15 BMM may reflect substrate 
re-diversion into the 5-LOX pathway in the absence of 12/15-LOX (Figure 5C). 
Interestingly, the 5-LOX pathway has been shown to promote granulocyte 
development through the production of leukotreine D4 (Miller et al., 1990). 
Moreover, inhibition of 5-LOX potentiated monocyte development (Stixova et al., 
2009). Although these studies were done on cell lines, they suggest that 5-LOX 
and 12/15-LOX have opposing roles in myeloid cell fate decisions. A balance of 
lipid mediator signaling may therefore be important for the regulation of myeloid 
cell development. 
 Because leukemia can result from aberrant myeloid cell development, 
elucidation of the processes that govern myelopoiesis may provide insight into 
leukemogenesis. Indeed, a small percentage of Alox15 mice developed a 
myeloid proliferative disease (MPD) over the course of a year, characterized by 
an accumulation of granulocytes (Middleton et al., 2006b). Moreover, IRF-8-
deficient mice, which exhibited a block in monocyte development and enhanced 
granulocyte development, developed a similar MPD (Holtschke et al., 1996). One 
can speculate that a block in monocyte development coupled with a skewing 
towards granulocyte development found in both Alox15 and IRF-8-deficient 
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mice may cause a favorable scenario for the development of a granulocytic 
leukemia. Indeed, an accumulation of GMP is also found during human chronic 
myelogenous leukemia and is believed to be the target of a secondary oncogenic 
event that drives the blast crisis phase of disease (Jamieson et al., 2004). 
 Redox regulation of IRF-8 nuclear accumulation and gene transcription 
may also play an important role during inflammation. Our lab previously showed 
that 12/15-LOX regulates IL-12p40 transcription in mature macrophages through 
IRF-8 (Middleton et al., 2006a). In this chapter we demonstrate that 12/15-LOX 
likely regulates IRF-8 nuclear accumulation and IL-12p40 gene transcription 
through ROS signaling in peripheral inflammatory macrophages, similar to our 
findings in immature BMM. Inflammation and inflammatory cytokines can induce 
ROS production and in turn ROS-signaling contributes to further inflammation 
and cytokine production (Haddad and Harb, 2005; Lambeth et al., 2008; 
Shakibaei et al., 2005). Similarly, increased ROS levels during inflammation may 
inhibit SHP1/2 leading to activation IRF-8 nuclear accumulation and 
transcriptional activity of inflammatory cytokines in mature macrophages. 
  In summary, we demonstrate that ROS-signaling regulates IRF-8 nuclear 
accumulation and subsequent monocyte differentiation in Alox15 mice. This 
results in an accumulation of defective GMP and a skewing towards 
granulopoiesis at the expense of monopoiesis in Alox15 mice. Restoration of 
ROS rescues Alox15 monocyte differentiation. Thus, these data establish a novel 
role for redox signaling in the regulation of nuclear accumulation and gene 
transcription by IRF-8 and in monocyte differentiation in Alox15 mice. These 
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findings have implications for leukemagenesis and inflammation. 
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DISCUSSION 
 My dissertation defined novel roles for polyunsaturated fatty acid 
metabolism mediated by 12/15-LOX during hematopoiesis. I found that 12/15-
LOX regulates the development of multiple hematopoietic cells including B cells, 
T cells, basophils, RBC, and monocytes and the function of HSCs (Figure 52). I 
demonstrate that disruption of 12/15-LOX signaling in Alox15 mice results in 
macrocytic anemia, decreased numbers of lymphocytes, impaired HSC function 
and skewed myeloid cell differentiation. The impaired HSC function and skewed 
myeloid cell differentiation likely underlie the development of the granulocytic 
MPN in a portion of Alox15 mice. Moreover, my data suggest that 12/15-LOX 
may regulate HSC function at least in part through canonical Wnt signaling and 
implicate redox signaling downstream of 12/15-LOX in the regulation of 
ICSBP/IRF-8 transcriptional activity and monocyte development. These signaling 
pathways have implications in the pathogenesis of immunity and cancer. 
Moreover, my studies are the first to establish a role for polyunsaturated fatty 
acid metabolism in vivo in the regulation of hematopoietic development and HSC 
function.  
Hematopoiesis 
 Although I have elucidated the mechanisms whereby 12/15-LOX regulates 
monocyte development and HSC function, the mechanisms whereby 12/15-LOX 
regulates B cell and T cell development remain of interest especially because 
12/15-lipoxygenases have not been previously shown to regulate lymphoid 
subsets. As we showed that 12/15-LOX regulates ICSBP/IRF-8 in multiple 
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cell types, it is likely that 12/15-LOX also regulates B cell development through 
ICSBP/IRF-8 as well. ICSBP/IRF-8 and a related transcription factor IRF-4 
regulate B cell development at the preB cells stage and are required for 
rearrangment of the IgG light chain (Lu et al., 2003) in part by mediating 
transcription of Ikaros and Aiolos (Ma et al., 2008). Moreover, ICSBP/IRF-8-
deficient mice and Alox15 mice exhibit similar defects in B cell development (Lu 
et al., 2003). Although the mechanism whereby 12/15-LOX regulates T cell 
development is not known, lipoxygenase products are found in the thymus (Harizi 
et al., 2008) and thus the defect in DP T cells in Alox15 mice may be due directly 
to alterations in lipid mediators. In addition to lymphoid subsets, the role of 12/15-
LOX during DC differentiation could be potentially interesting, although we have 
not yet explored this possibility. Because subsets of DC and monocytes share a 
common progenitor (Geissmann et al., 2008) and because ICSBP/IRF-8 is also 
known to regulate DC cell development (Aliberti et al., 2003; Tsujimura et al., 
2003), it is also possible that 12/15-LOX effects DC subsets. 
Myelopoiesis 
 Because the oxidative enzymes involved in unsaturated fatty acid 
metabolism compete for the same substrates, there may be cross-regulation 
between cytochrome p450s, cyclooxygenases and lipoxygenases during 
hematopoietic development due to substrate competition. In the absence of 
12/15-LOX, there may be substrate re-diversion and enhanced activity of other 
fatty acid enzymes. Indeed, we have shown that Alox15 BMM have increased 
levels of 5(S)-HETE, a product of 5-LOX (Figure 45). 5-LOX has been shown 
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to regulate granulocyte development through its product Leukotreine D4 (Miller et 
al., 1990). Moreover, inhibition of 5-LOX potentiates monocyte development, 
which is dependent upon p38MAPK activation (Stixova et al., 2009). On the other 
hand, inhibition of COX-2 has yielded mixed results during myeloid development 
(Hofmanova et al., 1998) (Bunce et al., 1994). Although, these studies were 
conducted in cell lines, they demonstrate a seemingly opposing effect for 5-LOX 
from what we have demonstrated for 12/15-LOX during monocyte development. 
It is likely a balance of these enzymes and their products regulate myeloid 
development (Figure 53). 
 The role of ROS signaling in myeloid development had not been 
previously established. Although ROS levels were known to increase 
macrophage development in part by NAPDH-oxidase (Barbieri et al., 2003), the 
role of ROS signaling in immature myeloid differentiation was not previously 
known. We demonstrated that ROS signaling generated by 12/15-LOX might 
actually specify monocyte differentiation by promoting ICSBP/IRF-8 nuclear 
accumulation. Moreover, we implicated SHP-2 as a redox sensitive factor 
important in the regulation of ICSBP/IRF-8 and in the subsequent specification of 
cell fate decisions. Although the role of ICSBP/IRF-8 in myeloid cell fate 
decisions had been well documented (Tsujimura et al., 2002; Tamura et al., 
2000), its regulation by redox signaling was not previously known. Because 
ICSBP/IRF-8 is present in multiple cell types other than myeloid progenitors 
including B cells, dendritic cells, T cells and macrophages (Nelson et al., 1996; 
Masumi et al., 2002; Tsujimura et al., 2003; Burchert et al., 2004) the 
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regulation of ICSBP/IRF-8 by redox signaling may play a role in multiple cell 
development and functions. Indeed, we showed that redox signaling might also 
regulate transcriptional activation of IL-12p40 in macrophages. 
 There are multiple pathways in which ROS are generated including 
NAPDH-oxidases, mitochondrial function and additional enzymes that participate 
in fatty acid metabolism (Haddad, 2002a). Therefore, other oxidative enzymes or 
cellular metabolism may participate in monocyte and granulocyte cell fate 
decisions through redox-mediated modulation of ICSBP/IRF-8 nuclear 
accumulation. However, it is possible that 12/15-LOX-mediated ROS production 
occurs in a site-specific and concentration-dependent manner to specifically 
regulate SHP-2 and ICSBP/IRF-8 during myelopoiesis and in mature 
macrophages. Our data from HSCs in Data Chapter 2, support this hypothesis. 
Although basal levels of ROS were increased in Alox15 LSK, 12/15-LOX-
dependent ROS were decreased. Moreover, Alox15 hematopoietic progenitors 
exhibited decreased nuclear accumulation of ICSBP/IRF-8 and Alox15 LSK had 
defective levels of ICSBP/IRF-8-mediated transcripts. Therefore, it is more likely 
that 12/15-LOX-dependent ROS is a specific regulator of ICSBP/IRF-8 
transcriptional activity, particularly in LSK. Nonetheless, it would be of interest to 
determine the selectivity of ROS in the regulation of ICSBP/IRF-8 in various cell 
types. 
 Although the role of SHP-2 in myeloid leukemia has been well 
documented (Loh et al., 2004; Niihori et al., 2005; Schubbert et al., 2005), the 
regulation of SHP-2 in myeloid cell fate decisions has only recently been 
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demonstrated (Jack et al., 2009). Moreover, the role of SHP-2 in myeloid 
differentiation is still under active investigation, as the contribution of SHP-1 
versus SHP-2 is not known (Jack et al., 2009). Both SHP-1 and SHP-2 are 
known to be negatively regulated by oxidative modification (Chen et al., 2009a; 
Heneberg and Draber, 2005; Meng et al., 2002; Weibrecht et al., 2007) and both 
can inhibit the transcriptional activity of ICSBP/IRF-8 through its de-
phosphorylation (Huang et al., 2006; Kautz et al., 2001). Since there was not a 
selective inhibitor for SHP-1 or SHP-2, we used a phosphatase inhibitor, NSC-
87877, which inhibited both SHP-1 and SHP-2. Therefore, either SHP-1, SHP-2 
or both may play a role in our signaling pathway by regulating ICSBP/IRF-8 
through ROS signaling generated by 12/15-LOX. A future direction would be to 
delineate the roles of SHP-1 and SHP-2 during monocyte and granulocyte cell 
fate decisions in both wild-type and Alox15 mice. 
HSC function 
 In addition to myelopoiesis, substrate competition for AA during fatty acid 
metabolism may also regulate HSC function as summarized in Figure 54. COX-1 
regulates formation of the hematopoietic niche while COX-2 directly regulates 
HSC self-renewal and function (North et al., 2007). Furthermore, the COX 
product PGE2 increases the number and function of LT-HSC (North et al., 2007) 
by increasing homing, survival, proliferation and self-renewal (Hoggatt et al., 
2009). PGE2 functions by stimulating its receptor on HSC, activating PKA and 
cAMP leading to stabilization of β-catenin by phosphorylation of GSK-3β and β-
catenin (Goessling et al., 2009). Although the specific mechanisms whereby 
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12/15-LOX and COX-2 regulate canonical Wnt signaling differ, 12/15-LOX 
ultimately functions similarly to COX-2 by promoting β-catenin stabilization. 
Interestingly, although 5-LOX does not play a major role in HSC function, it does 
promote HSC differentiation to some extent (Chen et al., 2009b).  Similar to its 
role during myelopoieis, 5-LOX signaling may oppose 12/15-LOX signaling, 
which we demonstrate functions to promote HSC self-renewal. 
 We demonstrated that basal levels of ROS are increased in Alox15 LSK. 
The increased basal levels of ROS in Alox15 LSK could be a result of decreased 
representation of LT-HSC, which express low levels of ROS compared to ST-
HSC and MPP and are increased within Alox15 LSK (Jang and Sharkis, 2007). 
However, the 12/15-LOX-independent ROS in HSC may be generated through 
NAPDH-oxidases (Piccoli et al., 2007), mitochondrial function (Chen et al., 2008) 
or other fatty acid oxidative enzymes such as 5-LOX (Chen et al., 2009b), which 
have all been shown to contribute to HSC metabolism. It is possible that the 
increased basal levels of ROS signal to negatively regulate HSC self-renewal 
through activation of p38MAPK (Ito et al., 2006). The contribution of ROS by 
12/15-LOX-dependent and independent mechanisms require further clarification. 
Because ROS can be generated by multiple mechanisms, ROS levels differ in 
various subcellular compartments, such as cell membrane versus mitochondrion, 
which may play a role in its subsequent signaling. Modulation of ROS levels in a 
subcellular compartment-dependent manner, will remain a challenge for future 
studies. 
Leukemia 
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 One result of altered hematopoiesis is leukemia. Disruptions in HSC 
signaling can result in myeloid leukemogenesis (Passegue et al., 2004; Jamieson 
et al., 2004; Yilmaz et al., 2006). Alternatively, a block in myeloid cell 
differentiation can also cause myeloid leukemias (Holtschke et al., 1996; 
Passegue et al., 2001; Mueller et al., 2002). However, these possibilities are not 
mutually exclusive. Furthermore, we demonstrate that Alox15-deficient mice 
exhibit disruptions in both HSC function and myeloid cell differentiation. It is likely 
that both altered HSC function and a block in monocyte differentiation contribute 
to the development of the CML-like leukemia in a proportion of Alox15 mice 
(Middleton et al., 2006b).  
 We demonstrate that 12/15-LOX-generated ROS regulated ICSBP/IRF-8 
nuclear accumulation possibly through SHP-2 inactivation. Interestingly, 
regulation of ICSBP/IRF-8 by SHP-2 had been implicated in leukemia. 
Constitutively active SHP-2 mutants synergized with haplo-insufficiency of 
ICSBP/IRF-8 to mediate AML (Konieczna et al., 2008). Moreover, oncogenic 
constitutively active SHP-2 mutants negatively regulated ICSBP/IRF-8 
expression of NF-1 (Huang et al., 2006). Loss of NF-1 expression by inhibition of 
ICSBP/IRF-8 contributed to leukemia progression (Koenigsmann et al., 2009). 
Our data proposes a model in which inhibition of 12/15-LOX found in myeloid 
leukemias (Stenke et al., 1991; Takayama et al., 1983) results in activation of 
SHP-2 and defective ICSBP/IRF-8 transcriptional activity contributing to leukemia 
progression.  
 Because 12/15-LOX regulated ICSBP/IRF-8 through redox regulation 
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of SHP-2, one would hypothesize that either increasing ROS or inhibiting SHP-2 
in Alox15 progenitors during leukemia could restore nuclear ICSBP to treat the 
CML-like MPN in Alox15 mice. Since Alox15 cells lost transcriptional expression 
of ICSBP during the leukemic phase of disease (Middleton et al., 2006b), 
increasing ROS levels or inhibiting SHP-2 in Alox15 mice may be used to prevent 
the development of leukemia rather than treat active leukemia. On the other 
hand, increasing ROS levels or inhibiting SHP-2 in Alox15 mice may cause 
activation of inflammatory gene transcription. Moreover, modulating ROS levels 
are difficult since their effects are dose-, cell- and subcellular-context dependent. 
 In the setting of leukemic HSC, fatty acid metabolism mediated by 5-LOX 
and 12/15-LOX may still have opposing functions (Figure 55). 5-LOX- deficient 
HSC or treatment of wild-type HSC with a 5-LOX inhibitor protects against Bcr-
Abl-induced CML (Chen et al., 2009b) demonstrating that 5-LOX positively 
regulates leukemic HSC function. During human CML, expression and activity of 
LTC4 synthase, an enzyme downstream of 5-LOX, was increased resulting in 
higher levels of Leukotriene C4 (Tornhamre et al., 2003). LTC4 increased 
proliferation of normal and leukemic hematopoietic progenitors in response to 
GM-CSF (Snyder et al., 1989; Stenke et al., 1993). On the other hand, we 
previously demonstrated that 12/15-LOX functions as a tumor suppressor and 
protects against development of a CML-like disease (Middleton et al., 2006b). 
Moreover, the common product of 5-LOX and 12/15-LOX Lipoxin A4 and a 12-
LOX product, 12(S)-HETE were decreased during human CML (Stenke et al., 
1991; Stenke et al., 1987). Furthermore, 12/15-LOX products promoted 
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apoptosis of K562 leukemic cell line (Mahipal et al., 2007). Therefore, 5-LOX 
promotes leukemogenesis and its products are increased during human CML, 
12/15-LOX functions as a tumor suppressor and its products are decreased 
during human CML. It is possible that substrate re-diversion in the absence of 
12/15-LOX contributes to the CML-like MPN in Alox15 mice. 
 While 5-LOX and 12/15-LOX may oppose each other during 
leukemogenesis, the role of COXs are less understood. While COX inhibitors did 
not effect proliferation or apoptosis of leukemic cell lines (Snyder et al., 1989), 
COX products Prostaglandin D2 and Prostaglandin J2 induced their cell death 
(Chen et al., 2005). Thus, the role of COX-1 and COX-2 during leukemic 
development requires further study. 
Immunity  
 My data demonstrated that ROS signaling downstream of 12/15-LOX 
mediated IL-12p40 gene expression in macrophages. Although it was previously 
known that ROS signaling increases inflammatory gene transcription (Haddad, 
2002b), we now demonstrate that signaling of ROS specifically generated by 
12/15-LOX contributes to inflammatory cytokine gene expression. We identify 
ICSBP/IRF-8 as a novel target downstream of redox signaling. As we previously 
showed that NF-κB-mediated gene transcription of IL-12p40 was regulated by 
12/15-LOX (Middleton et al., 2006a) and as it was known that NF-κB is regulated 
by redox signaling (Haddad, 2002a), it is likely that ROS signaling mediated by 
12/15-LOX also regulates NF-κB transcriptional activity. 
 Although we demonstrated that ROS signaling downstream of 12/15-
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LOX regulated ICSBP/IRF-8 transcriptional activity, it is also likely that ROS 
generated independently of 12/15-LOX regulates ICSBP/IRF-8 inflammatory 
gene transcription. Inflammation and inflammatory cytokines can induce ROS 
production through multiple mechanisms and in turn ROS-signaling contributes to 
further inflammation and cytokine production (Haddad and Harb, 2005; Lambeth 
et al., 2008; Shakibaei et al., 2005). Similarly, increased ROS levels during 
inflammation may activate IRF-8 nuclear accumulation and transcriptional activity 
of inflammatory cytokines in mature macrophages.   
 The role of 12/15-LOX has been extensively studied in the context of 
chronic inflammation. For instance, it was known that 12/15-LOX contributed to 
chronic inflammation and immunity in atherosclerosis and toxoplasma infection 
(Cyrus et al., 2001; George et al., 2001; Zhao et al., 2002; Middleton, et al in 
press). Moreover, it was known that 12/15-LOX regulated expression of 
inflammatory cytokines in macrophages (Middleton et al., 2006a; Dioszeghy et 
al., 2008). However, the signaling pathways whereby 12/15-LOX regulated 
inflammatory gene transcription were not well understood. My studies 
demonstrate a mechanism whereby 12/15-LOX may regulate inflammatory gene 
transcription through redox signaling.  
Cancer  
 In addition to leukemia, fatty acid metabolism mediated by 12/15-LOX may 
also mediate solid tumor progression. Although my data demonstrate how 12/15-
LOX mediates signaling in hematopoietic cell types, it would be interesting to 
determine whether 12/15-LOX promotes self-renewal during solid tumor 
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progression similarly to how it regulates self-renewal of LSK. On the other hand, 
since 12/15-LOX functions as a tumor suppressor in leukemia (Middleton et al., 
2006b), it is possible that 12/15-LOX functions as a tumor suppressor during 
solid tumor progression. Our pathways demonstrate that 12/15-LOX may signal 
through the immune cell specific transcription factor ICSBP/IRF-8 in 
hematopoietic cells to mediate their effects. Nonetheless, since non-
hematopoietic cells do not express ICSBP/IRF-8, it would be interesting to 
determine whether there are effects of 12/15-LOX independent of ICSBP/IRF-8 
on self-renewal, proliferation and cellular differentiation. Importantly, 12/15-LOX 
may regulate canonical Wnt signaling and self-renewal independently of 
ICSBP/IRF-8, possibly in a similar manner as the COX-2 and its product PGE2 
(Goessling et al., 2009).  
  It was known that fatty acid metabolism of AA contributes to solid tumor 
progression (Figure 56). While COX-1 is constitutively expressed in the majority 
of both normal and neoplastic tissues, over-expression of COX-2 in both 
epithelial and leukocyte compartments has been observed in many cancer types 
including breast, esophageal, gastric, lung, prostate and pancreatic cancer 
(Furstenberger et al., 2006). Moreover, use of non-steroidal anti-inflammatory 
drugs (NSAIDs) such as aspirin, which function in part by targeting COX, can 
reduce incidence and recurrence of several human cancers by up to 50% (Hyde 
and Missailidis, 2009). More specific COX-2 inhibitors have been used in studies 
to prevent colon cancer in high-risk populations. However, its long-term use is 
limited because of increased risk of thrombotic events as described in the 
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introduction of this dissertation. COX-2 functions to promote cancer by 
stimulating inflammation, cancer cell proliferation, angiogenesis, cancer cell 
survival and invasiveness. It signals in part through its lipid products, PGE2 and 
PGF2 to activate RAS-MAPK and Wnt pathways (Furstenberger et al., 2006). 
Interestingly, COX-2 activates Wnt signaling in multiple cancers similarly to how it 
activates Wnt signaling in HSC, through inhibition of GSK3β resulting in 
increased levels of β-catenin (Lim et al., 2008; Lu et al., 2009; Tuynman et al., 
2008). Wnt signaling promotes cell proliferation and self-renewal during cancer, 
and its constitutive activation is oncogenic. 
 The role of lipoxygenases during cancer progression is more complicated. 
The isoenzymes 5-LOX, platelet-12-LOX (p12-LOX) are pro-carcinogenic while 
15-LOX-2 (mouse ortholog 8-LOX) is anti-carcinogenic. The role of 15-LOX-1 
(mouse ortholog 12/15-LOX) is pro-carcinogenic in prostate cancer but anti-
carcinogenic during other cancer types. 5-LOX and p12-LOX are absent from 
normal tissues, induced by inflammatory stimuli and over-expressed in colon, 
esophageal, lung, prostate and breast cancer. Meanwhile, 15-LOX-1 and 15-
LOX-2 are generally expressed only in benign tissues and not in carcincomas. In 
some cancers decreased expression of 15-LOX coupled with increased 
expression of p12-LOX is a prognostic of poor tumor outcome. 5-LOX and p12-
LOX increase cancer cell proliferation, survival and invasiveness. Both 5-LOX 
and p12-LOX promote angiogenesis by stimulating endothelial cell proliferation 
and inducing VEGF expression. Inhibition of 5-LOX or p12-LOX results in 
apoptosis of breast cancer, colon, gastric, lung and prostate cancers 
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(Pidgeon et al., 2007). Moreover, inhibition of multiple LOX and COX in 
combination (such has inhibition of 5-LOX and COX-2) may be beneficial since 
substrate re-diversion occurs resulting in increased activation of one pathway 
when the other is inhibited (Schroeder et al., 2007). On the other hand 15-LOX-2 
functions as a tumor suppressor in multiple cancer types by promoting cell 
differentiation and senescence (Pidgeon et al., 2007; Tang et al., 2007).  
 Although 15-LOX-1 is anti-carcinogenic for most cancer types, its role in 
prostate cancer is pro-carcinogenic. 15-LOX-1 expression is correlated to tumor 
grade in human prostate cancers (Pidgeon et al., 2007) and expression of its 
murine ortholog 12/15-LOX is induced in multiple mouse models of prostate 
cancer (Shappell et al., 2003; Kelavkar et al., 2004). In addition, induced 
expression of 15-LOX-1 in the prostate results in epithelial proliferation and 
prostatic intraepithelial neoplasia (Kelavkar et al., 2006). The apparent 
discrepancy in the role of 15-LOX-1 in distinct tumor types can be resolved by 
comparing the products involved. The lipid mediators 12(S)-HETE and 13(S)-
HODE are pro-carcinogenic while 15(S)-HETE is generally anti-carcinogenic 
(Figure 56). 12(S)-HETE activated NF-κB, Erk and p38MAPK to stimulate cell 
growth, angiogenesis and invasiveness. 13(S)-HODE increased MAPK and Akt 
activation while 15(S)-HETE decreased activation of MAPK and Akt (Pidgeon et 
al., 2007). Human p12-LOX generates 12(S)-HETE exclusively while 15-LOX-1 
generates both 13(S)-HODE and 15(S)-HETE and 15-LOX-2 generates 15(S)-
HETE exclusively. 15-LOX-1 may produce different levels of 13(S)-HODE and 
15(S)-HETE in different cell types in the prostate. Nonetheless murine 12/15-
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LOX produces 12(S)-HETE and 15(S)-HETE at a ratio of 3:1 (Chen et al., 1994) 
in addition to generating 13(S)-HODE. It is likely that murine 12/15-LOX functions 
more similarly to human p12LOX because of the higher levels of pro-
carcinogenic 12(S)-HETE produced rather than its human ortholog 15-LOX-1 
which does not produce a substantial amount of 12(S)-HETE.  
The study of 12/15-LOX products during tumor progression stresses the 
importance of understanding the balance of products and downstream signaling 
pathways. Substrate re-diversion may also play a role during Alox15 
carcinogenesis. It would be interesting to explore whether increased COX and 5-
LOX activity could contribute to carcinogenesis in Alox15 mice. 
 Since human p12-LOX and 12/15-LOX are pro-carcinogenic, it would be 
of interest to determine whether they promote cancer proliferation through Wnt 
activation similarly to COX-2. Specifically, because the pro-carcinogenic lipid 
mediators 12(S)-HETE and 13(S)-HODE were decreased in Alox15 HSC which 
had defective canonical Wnt signaling, 12(S)-HETE and 13(S)-HODE may 
regulate Wnt signaling and self-renewal to promote cancer progression. The 
effect of 12/15-LOX as a tumor suppressor in leukemia may be dependent on 
ICSBP/IRF-8 since it does not function as a tumor suppressor in solid tumors. 
Although 15(S)-HETE is anti-carcinogenic in solid tumors, it is unlikely to be anti-
carcinogenic during leukemia since its levels are not changed during human CML 
and Alox15 CML-like MPN (Middleton et al., 2006b) (Stenke et al., 1987). 
Summary  
 In summary, my dissertation demonstrates critical roles for 12/15-LOX 
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in hematopoietic development of multiple cell types. These are the first studies 
that effectively demonstrate a role for fatty acid metabolism in hematopoietic 
development in vivo. I have defined novel signaling pathways in HSC function 
and myeloid development. 12/15-LOX promotes self-renewal and maintains 
quiescence of HSC through canonical Wnt signaling. Moreover, 12/15-LOX 
mediates monocyte differentiation and inhibits granulocyte differentiation through 
redox regulation of ICSBP/IRF-8 transcriptional activity through SHP-2. I have 
shown that this signaling pathway is also likely intact during macrophage 
regulation of IL-12p40, which has implications for inflammation and immunity. 
Moreover, these data provide insight into HSC function and myelopoiesis. The 
signaling pathways that I have elucidated likely underlie development of the 
CML-like MPN in Alox15 mice and therefore have implications for 
leukemogenesis and tumorigenesis. 
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